U.S. patent number 11,180,759 [Application Number 16/842,404] was granted by the patent office on 2021-11-23 for methods and compositions using rna interference and antisense oligonucleotides for inhibition of kras.
This patent grant is currently assigned to The University of North Carolina at Chapel Hill. The grantee listed for this patent is The University of North Carolina at Chapel Hill. Invention is credited to Salma H. Azam, Chad Pecot.
United States Patent |
11,180,759 |
Pecot , et al. |
November 23, 2021 |
Methods and compositions using RNA interference and antisense
oligonucleotides for inhibition of KRAS
Abstract
The invention relates to the inhibition of expression of mutant
KRAS sequences using RNA interference, antisense oligonucleotides,
and chemically-modified oligonucleotides.
Inventors: |
Pecot; Chad (Pittsboro, NC),
Azam; Salma H. (Cary, NC) |
Applicant: |
Name |
City |
State |
Country |
Type |
The University of North Carolina at Chapel Hill |
Chapel Hill |
NC |
US |
|
|
Assignee: |
The University of North Carolina at
Chapel Hill (Chapel Hill, NC)
|
Family
ID: |
71835962 |
Appl.
No.: |
16/842,404 |
Filed: |
April 7, 2020 |
Prior Publication Data
|
|
|
|
Document
Identifier |
Publication Date |
|
US 20200248185 A1 |
Aug 6, 2020 |
|
Related U.S. Patent Documents
|
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
Issue Date |
|
|
16070600 |
Apr 14, 2020 |
10619159 |
|
|
|
PCT/US2017/014013 |
Jan 19, 2017 |
|
|
|
|
62280458 |
Jan 19, 2016 |
|
|
|
|
Current U.S.
Class: |
1/1 |
Current CPC
Class: |
C12N
15/1135 (20130101); A61P 35/00 (20180101); C12N
2310/11 (20130101); C12N 2310/341 (20130101); C12N
2310/3231 (20130101); C12N 2310/14 (20130101); C12N
2310/346 (20130101); C12N 2310/315 (20130101); C12N
2310/3525 (20130101); C12N 2320/34 (20130101); C12N
2310/321 (20130101); C12N 2310/3525 (20130101) |
Current International
Class: |
C12N
15/113 (20100101); A61P 35/00 (20060101) |
References Cited
[Referenced By]
U.S. Patent Documents
Foreign Patent Documents
|
|
|
|
|
|
|
2010/001325 |
|
Jan 2010 |
|
WO |
|
2010/115206 |
|
Oct 2010 |
|
WO |
|
2012/138739 |
|
Oct 2012 |
|
WO |
|
2012/171015 |
|
Dec 2012 |
|
WO |
|
Other References
US. Appl. No. 16/070,600, filed Jul. 17, 2018; Office Action dated
Apr. 1, 2019. cited by applicant .
U.S. Appl. No. 16/070,600, filed Jul. 17, 2018; Office Action dated
Aug. 28, 2019. cited by applicant .
Cox et al. "Drugging the undruggable Ras: missing possible?", Nat
Rev Drug Discov., 13(11):828-851 (2014). cited by applicant .
Extended European Search Report corresponding to European
Application No. 17741876.1 dated Aug. 16, 2019. cited by applicant
.
International Preliminary Report on Patentability corresponding to
International Application No. PCT/US2017/014013 dated Aug. 2, 2018.
cited by applicant .
Lin et al. "KRAS Mutation is a Predictor of Oxaliplatin Sensitivity
in Colon Cancer Cells", PLOS One 7(11):e50701 (2012) 11 pages.
cited by applicant .
Notification of Transmittal of the International Search Report and
the Written Opinion of the International Searching Authority, or
the Declaration corresponding to International Application No.
PCT/US2017/014013 dated May 4, 2017. cited by applicant .
Rachagani et al. "Clinical implications of miRNAs in the
pathogenesis, diagnosis and therapy of pancreatic cancer", Adv Drug
Deliv Rev., 81:16-33 (2015). cited by applicant .
"International Search Report and Written Opinion corresponding to
International Application No. PCT/US2021/026147 dated Jul. 28,
2021". cited by applicant.
|
Primary Examiner: Vivlemore; Tracy
Attorney, Agent or Firm: Myers Bigel, P.A.
Parent Case Text
STATEMENT OF PRIORITY
This application is a continuation-in-part of U.S. application Ser.
No. 16/070,600, filed Jul. 17, 2018, which is a 35 U.S.C. .sctn.
371 national phase application of PCT Application PCT/US20171014013
filed Jan. 19, 2017, which claims the benefit of U.S. Provisional
Application Ser. No. 62/280,458, filed Jan. 19, 2016, the entire
contents of each of which are incorporated by reference herein in
its entirety.
Claims
What is claimed is:
1. A siRNA molecule targeted to a naturally-occurring human KRAS
mRNA encoding a mutation selected from G12C, G12D, G12V, or G13D,
wherein the siRNA molecule is fully chemically-modified, and
wherein the siRNA molecule comprises one of the following pairs of
sequences: sense strand of SEQ ID NO:128 and antisense strand of
SEQ ID NO:129; sense strand of SEQ ID NO:130 and antisense strand
of SEQ ID NO:131; sense strand of SEQ ID NO:132 and anti sense
strand of SEQ ID NO:133; sense strand of SEQ ID NO:134 and anti
sense strand of SEQ ID NO:135; sense strand of SEQ ID NO:136 and
antisense strand of SEQ ID NO:137; sense strand of SEQ ID NO:138
and antisense strand of SEQ ID NO:139; sense strand of SEQ ID
NO:140 and antisense strand of SEQ ID NO:141; sense strand of SEQ
ID NO:142 and anti sense strand of SEQ ID NO:143; sense strand of
SEQ ID NO:144 and anti sense strand of SEQ ID NO:145; sense strand
of SEQ ID NO:146 and antisense strand of SEQ ID NO:147; sense
strand of SEQ ID NO:148 and antisense strand of SEQ ID NO:149;
sense strand of SEQ ID NO:150 and anti sense strand of SEQ ID
NO:151; sense strand of SEQ ID NO:152 and anti sense strand of SEQ
ID NO:153; sense strand of SEQ ID NO:154 and antisense strand of
SEQ ID NO:155; sense strand of SEQ ID NO:156 and antisense strand
of SEQ ID NO:157; or sense strand of SEQ ID NO:158 and antisense
strand of SEQ ID NO:159; or a sequence at least 90% identical
thereto.
2. The siRNA molecule of claim 1, wherein the siRNA molecule
comprises at least one phosphorothioate linkage.
3. The siRNA molecule of claim 1, comprising a sense strand and an
antisense strand, wherein the siRNA molecule comprises one of the
following pairs of sequences: sense strand of SEQ ID NO:78 and
antisense strand of SEQ ID NO:79; sense strand of SEQ ID NO:80 and
antisense strand of SEQ ID NO:81; sense strand of SEQ ID NO:82 and
anti sense strand of SEQ ID NO:83; sense strand of SEQ ID NO:84 and
antisense strand of SEQ ID NO:85; sense strand of SEQ ID NO:86 and
antisense strand of SEQ ID NO:87; sense strand of SEQ ID NO:88 and
antisense strand of SEQ ID NO:89; sense strand of SEQ ID NO:90 and
anti sense strand of SEQ ID NO:91; sense strand of SEQ ID NO:92 and
anti sense strand of SEQ NO:93; sense strand of SEQ ID NO:94 and
antisense strand of SEQ ID NO:95; sense strand of SEQ ID NO:96 and
antisense strand of SEQ ID NO:97; sense strand of SEQ ID NO:98 and
antisense strand of SEQ ID NO:99; sense strand of SEQ ID NO:100 and
antisense strand of SEQ ID NO:101; sense strand of SEQ ID NO:102
and antisense strand of SEQ ID NO:103; sense strand of SEQ ID
NO:104 and antisense strand of SEQ ID NO:105; sense strand of SEQ
ID NO:106 and antisense strand of SEQ ID NO:107; or sense strand of
SEQ ID NO:108 and antisense strand of SEQ ID NO:109.
4. A pharmaceutical composition comprising the siRNA molecule of
claim 1 and a pharmaceutically acceptable carrier.
5. A method of inhibiting expression of a mutant human KRAS gene
comprising one or more of the missense mutations G12C, G12V, and
G13D in a cell, the method comprising contacting the cell with the
siRNA molecule of claim 1, thereby inhibiting expression of the
mutant human KRAS gene in the cell.
6. A method of treating cancer in a subject in need thereof,
wherein the cancer comprises a mutant human KRAS gene comprising
one or more of the missense mutations G12C, G12D, G12V, and G13D,
the method comprising delivering to the subject the siRNA molecule
of claim 1, thereby treating cancer in the subject.
7. The siRNA molecule of claim 1, wherein each nucleotide in the
siRNA molecule is modified with a 2'-O-methyl group or a 2'-fluoro
group.
8. An siRNA molecule targeted to human KRAS mRNA, wherein the sense
strand of the siRNA comprises the sequence of SEQ ID NO:50 or SEQ
ID NO:51, and wherein the siRNA is fully chemically-modified.
9. The siRNA molecule of claim 8, wherein each nucleotide in the
siRNA molecule is modified with a 2'-O-methyl group or a 2'-fluoro
group.
10. The siRNA molecule of claim 8, wherein the siRNA molecule
comprises at least one phosphorothioate linkage.
11. The siRNA molecule of claim 8, comprising a sense strand and an
antisense strand, wherein the siRNA molecule comprises one of the
following pairs of sequences: sense strand of SEQ ID NO:110 and
antisense strand of SEQ ID NO:111; or sense strand of SEQ ID NO:112
and antisense strand of SEQ ID NO:113.
12. A composition comprising the siRNA of claim 1.
13. A composition comprising two or more of the siRNAs of claim 1
in any combination, wherein the two or more siRNAs each comprise a
different sequence.
14. The composition of claim 12, further comprising a
nanoparticle.
15. The composition of claim 14, wherein the nanoparticle is a
nanoliposome.
16. The method of claim 6, wherein the delivery is systemic
delivery.
Description
STATEMENT REGARDING ELECTRONIC FILING OF A SEQUENCE LISTING
A Sequence Listing in ASCII text format, submitted under 37 C.F.R.
.sctn. 1.821, entitled 5470-773IP_ST25.txt, 59,614 bytes in size,
generated on Apr. 6, 2020 and filed via EFS-Web, is provided in
lieu of a paper copy. This Sequence Listing is hereby incorporated
by reference into the specification for its disclosures.
FIELD OF THE INVENTION
The invention relates to the inhibition of expression of mutant
KRAS sequences using RNA interference, antisense oligonucleotides,
and chemically-modified oligonucleotides.
BACKGROUND OF THE INVENTION
Since its discovery in 1982, the RAS family of genes has been
characterized as an important class of proto-oncogenes (Cox et al.,
Nat. Rev. Drug Discov. 13:828 (2014)). Through three decades of
extensive research, mutational activation of certain RAS genes
(KRAS, NRAS, and HRAS) has been implicated in nearly one-third of
all cancers (Pecot et al., Mol. Cancer Ther. 13:2876 (2014)). In
particular, KRAS mutations are observed most frequently, both
exclusively and in conjunction with the other RAS isoforms (Cox et
al., Nat. Rev. Drug Discov. 13:828 (2014)). Yet in spite of efforts
to develop inhibitors for this highly prevalent mutation, no strong
therapeutic candidates have emerged, thus earning the KRAS gene its
reputation as an elusively "undruggable" target.
The RAS genes encode a family of small GTPases that act upon
downstream effector proteins to promote cell survival, growth, and
proliferation (Khosravi-Far et al., Cancer Metastasis Rev. 13:67
(1994)). Proper function of the RAS proteins relies upon activation
via a guanine nucleotide exchange factor (GEF) to its active,
GTP-bound form as well as membrane association of the RAS-GTP
complex, both of which have been proposed as targets for KRAS
inhibition. However, due to low efficacy and target specificity of
previously proposed therapeutic agents in directly inhibiting KRAS,
current measures to target the KRAS pathway focus predominantly on
inhibition of downstream effector proteins (Cox et al., Nat. Rev.
Drug Discov. 13:828 (2014)). Nevertheless, despite challenges in
developing a small molecule to directly down-regulate gene
activity, KRAS remains a therapeutically relevant target due to its
prevalence as a driving mutation in human cancers.
Advances in RNA interference (RNAi) suggest its potential as an
effective means of knocking down KRAS expression. RNAi therapy uses
the interaction of an exogenous small interfering RNA (siRNA) and
endogenous enzymatic machinery, termed an RNA-induced silencing
complex (RISC), to selectively silence specific genes at the mRNA
level (Pecot et al., Nat. Rev. Cancer 11:59 (2011)). A recent study
has revealed the efficacy of RNAi as a well-tolerated therapy for
inducing metastatic regression in human cancer patients (Tabernero
et al., Cancer Discov. 3:406 (2013)). In addition, using
nanoliposomes we have recently verified the efficacy of siRNA
delivery for knockdown of human KRAS in various lung and colon
cancer models, both in vitro and in vivo (Pecot et al., Mol. Cancer
Ther. 13:2876 (2014)).
However, there remains a lack of target-specificity for mutant KRAS
over the wild-type (WT) allele. Despite the oncogenic properties of
the mutant allele, WT KRAS is necessary for proper response to
extra-cellular inputs that promote viability in non-cancerous cells
(Khosravi-Far et al., Cancer Metastasis Rev. 13:67 (1994)). As
such, there is a need for inhibitors that target mutant KRAS while
sparing WT KRAS.
Accordingly, the present invention overcomes the deficiencies in
the art by providing compositions and methods using RNA
interference for specific inhibition of mutant KRAS sequences.
SUMMARY OF THE INVENTION
The present invention is based on the identification of RNA
molecules that inhibit expression of mutant KRAS sequences while
sparing expression of WT KRAS. Accordingly, one aspect of the
invention relates to a double stranded RNA molecule comprising an
antisense strand and a sense strand, wherein the nucleotide
sequence of the antisense strand is complementary to a region of
the nucleotide sequence of a synthetic human KRAS gene that
contains the missense mutations G12C, G12D, and G13D or the
missense mutations G12C, G12V, and G13D, the region consisting
essentially of about 18 to about 25 consecutive nucleotides;
wherein the double stranded RNA molecule inhibits expression of a
mutant human KRAS gene comprising one or more of the missense
mutations G12C, G12D, G12V, and G13D and minimally inhibits
expression of wild-type human KRAS.
Another aspect of the invention relates to a composition, e.g., a
pharmaceutical composition, comprising one or more of the RNA
molecules of the invention.
A further aspect of the invention relates to a method of inhibiting
expression of a mutant human KRAS gene comprising one or more of
the missense mutations G12C, G12D, G12V, and G13D in a cell, the
method comprising contacting the cell with the RNA molecule of the
invention, thereby inhibiting expression of the mutant human KRAS
gene in the cell.
An additional aspect of the invention relates to a method of
treating cancer in a subject in need thereof, wherein the cancer
comprises a mutant human KRAS gene comprising one or more of the
missense mutations G12C, G12D, G12V, and G13D, the method
comprising delivering to the subject the RNA molecule of the
invention, thereby treating cancer in the subject.
Another aspect of the invention relates to the use of the RNA
molecules of the invention to inhibit expression of a mutant human
KRAS gene comprising one or more of the missense mutations G12C,
G12D, G12V, and G13D in a cell and to treat cancer in a subject in
need thereof, wherein the cancer comprises a mutant human KRAS gene
comprising one or more of the missense mutations G12C, G12D, G12V,
and G13D.
A further aspect of the invention relates to an antisense
oligonucleotide targeted to a synthetic human KRAS mRNA that
encodes the missense mutations G12C, G12D, and G13D, wherein the
antisense oligonucleotide is 16-25 nucleotides in length and
comprises the sequence TCTTGCCTACGTCATA (SEQ ID NO:114).
An additional aspect of the invention relates to an antisense
oligonucleotide targeted to a naturally-occurring human KRAS mRNA
encoding a mutation selected from G12C, G12D, G12V, and G13D,
wherein the antisense oligonucleotide is 16-25 nucleotides in
length and comprises a sequence selected from:
a) TCTTGCCTACGCCACA (SEQ ID NO:117) targeted to a human KRAS mRNA
encoding a G12C mutation;
b) TCTTGCCTACGCCATC (SEQ ID NO: targeted to a human KRAS mRNA
encoding a G12D mutation;
c) TCTTGCCTACGCCAAC (SEQ ID NO:119) targeted to a human KRAS mRNA
encoding a G12V mutation;
d) TCTTGCCTACGTCACC (SEQ ID NO:120) targeted to a human KRAS mRNA
encoding a G13D mutation; or
e) a sequence at least 90% identical to any one of a) to d) wherein
the antisense oligonucleotide comprises at least one non-naturally
occurring chemical modification.
Another aspect of the invention relates to a siRNA molecule
targeted to a naturally-occurring human KRAS mRNA encoding a
mutation selected from G12C, G12D, G12V, and G13D, wherein the
siRNA molecule comprises at least one chemical modification, and
wherein the siRNA molecule comprises one of the following pairs of
sequences:
sense strand of SEQ ID NO:128 and antisense strand of SEQ ID
NO:129;
sense strand of SEQ ID NO:130 and antisense strand of SEQ ID
NO:131;
sense strand of SEQ ID NO:132 and antisense strand of SEQ ID
NO:133;
sense strand of SEQ ID NO:134 and antisense strand of SEQ ID
NO:135;
sense strand of SEQ ID NO:136 and antisense strand of SEQ ID
NO:137;
sense strand of SEQ ID NO:138 and antisense strand of SEQ ID
NO:139;
sense strand of SEQ ID NO:140 and antisense strand of SEQ ID
NO:141;
sense strand of SEQ ID NO:142 and antisense strand of SEQ ID
NO:143;
sense strand of SEQ ID NO:144 and antisense strand of SEQ ID
NO:145;
sense strand of SEQ ID NO:146 and antisense strand of SEQ ID
NO:147;
sense strand of SEQ ID NO:148 and antisense strand of SEQ ID
NO:149;
sense strand of SEQ ID NO:150 and antisense strand of SEQ ID
NO:151;
sense strand of SEQ ID NO:152 and antisense strand of SEQ ID
NO:153;
sense strand of SEQ ID NO:154 and antisense strand of SEQ ID
NO:155;
sense strand of SEQ ID NO:156 and antisense strand of SEQ ID
NO:157; or
sense strand of SEQ ID NO:158 and antisense strand of SEQ ID
NO:159; or a sequence at least 90% identical thereto.
An additional aspect of the invention relates to an siRNA molecule
targeted to human KRAS mRNA, wherein the sense strand of the siRNA
comprises the sequence of SEQ ID NO:50 or SEQ ID NO:51, and wherein
the siRNA comprises at least one non-naturally occurring chemical
modification.
Another aspect of the invention relates to a composition, e.g., a
pharmaceutical composition, comprising one or more of the antisense
oligonucleotides or siRNAs molecules of the invention.
A further aspect of the invention relates to a method of inhibiting
expression of a mutant human KRAS gene comprising one or more of
the missense mutations G12C, G12D, G12V, and G13D in a cell, the
method comprising contacting the cell with the antisense
oligonucleotides or siRNAs molecules of the invention, thereby
inhibiting expression of the mutant human KRAS gene in the
cell.
An additional aspect of the invention relates to a method of
treating cancer in a subject in need thereof, wherein the cancer
comprises a mutant human KRAS gene comprising one or more of the
missense mutations G12C, G12D, G12V, and G13D, the method
comprising delivering to the subject the antisense oligonucleotides
or siRNAs molecules of the invention, thereby treating cancer in
the subject.
Another aspect of the invention relates to the use of the antisense
oligonucleotides or siRNAs molecules of the invention to inhibit
expression of a mutant human KRAS gene comprising one or more of
the missense mutations G12C, G12D, G12V, and G13D in a cell and to
treat cancer in a subject in need thereof, wherein the cancer
comprises a mutant human KRAS gene comprising one or more of the
missense mutations G12C, G12D, G12V, and G13D.
These and other aspects of the invention are set forth in more
detail in the description of the invention below.
BRIEF DESCRIPTION OF THE DRAWINGS
FIG. 1 shows KRAS siRNA sequences (SEQ ID NOS:40-51), TMS siRNA
sequences were designed to bind the G domain of the human KRAS gene
at codons 12 and 13 and target three point mutations (each
indicated with an asterisk). Underlining indicates the remaining
base pairs targeted by the siRNA (sense). Sequences for G12C and
G12D siRNAs were obtained from Fleming et al., Mol. Cancer Res.
3:413 (2005). Positive control siRNAs (Seq2 and Seq3) were obtained
from Pecot et al., Mol. Cancer Ther. 13:2876 (2014) and targeted a
downstream coding region of the KRAS mRNA.
FIGS. 2A-2B show KRAS expression levels with mutant-specific (MS)
and control siRNAs. NIH 3T3 cells infected with human WT, G12C,
G12D, G12V, or G13D KRAS were reverse transfected with either (A)
MS siRNA sequences (12CD13D_1, 12CD13D_2, 12CD13D_3, 12CD13D_4,
12CV13D_1, and 12CV13D_2) or (B) control mutant-specific siRNA or
non-specific sequences.
FIG. 3 shows the testing of custom KRAS siRNA sequences 12CD13D_1
and 12CD13D_4 in a KRAS G12D mutant lung cancer cell line.
FIG. 4 shows the library of siRNA sequences (SEQ ID NOS:45-51) used
for testing all possible siRNA sequence permutations between the
custom siRNA sequences.
FIG. 5 shows the relative expression of wild-type and mutant KRAS
mRNAs in 3T3 cells.
FIG. 6 shows a schematic of the antisense oligonucleotide screen
against the synthetic KRAS gene (SEQ ID NOS:52 and 53).
FIG. 7 shows the ability of 16 antisense oligonucleotides to
inhibit mutant KRAS expression in A431 cells. The A431 cells have
been genetically-engineered to have the KRAS wild-type allele
removed and individual A431 clones were created to express the
human KRAS mutant alleles, either KRAS G12C, KRAS G12D, KRAS G12V,
or KRAS G13D (as shown); thus controlling for gymnotic delivery
mechanisms, oligonucleotide trafficking and RNAse H silencing
activity.
FIG. 8 shows the ability of 6 antisense oligonucleotides to inhibit
mutant KRAS expression in genetically-engineered A431 cells at
different concentrations.
FIG. 9 shows the ability of chemically-modified ASO16 antisense
oligonucleotides to inhibit mutant KRAS expression in
genetically-engineered A431 cells.
FIG. 10 shows the activity of fully modified siRNAs targeted to the
KRAS G12C mutation in genetically-engineered A431 cells expressing
KRAS G12C.
FIG. 11 shows the activity of fully modified siRNAs targeted to the
KRAS G12C mutation in genetically-engineered A431 cells expressing
KRAS G12C.
FIG. 12 shows the activity of fully modified siRNAs targeted to the
KRAS G12D mutation in genetically-engineered A431 cells expressing
KRAS G12D.
FIG. 13 shows the activity of fully modified siRNAs targeted to the
KRAS G12D mutation in genetically-engineered A431 cells expressing
KRAS G12D.
FIG. 14 shows the activity of fully modified siRNAs targeted to the
KRAS G12V mutation in genetically-engineered A431 cells expressing
KRAS G12V.
FIG. 15 shows the activity of fully modified siRNAs targeted to the
KRAS G12V mutation in genetically-engineered A431 cells expressing
KRAS G12V.
FIG. 16 shows the activity of fully modified siRNAs targeted to the
KRAS G13D mutation in genetically-engineered A431 cells expressing
KRAS G13D.
FIG. 17 shows the activity of fully modified siRNAs targeted to the
KRAS G13D mutation in genetically-engineered A431 cells expressing
KRAS G13D.
FIG. 18 shows the activity of fully modified siRNAs targeted to
KRAS in HCT116 (KRAS G13D mutant) and LU65 (KRAS G12C mutant)
cells.
DETAILED DESCRIPTION OF THE INVENTION
The present invention will now be described in more detail with
reference to the accompanying drawings, in which preferred
embodiments of the invention are shown. This invention may,
however, be embodied in different forms and should not be construed
as limited to the embodiments set forth herein. Rather, these
embodiments are provided so that this disclosure will be thorough
and complete, and will fully convey the scope of the invention to
those skilled in the art.
Unless otherwise defined, all technical and scientific terms used
herein have the same meaning as commonly understood by one of
ordinary skill in the art to which this invention belongs. The
terminology used in the description of the invention herein is for
the purpose of describing particular embodiments only and is not
intended to be limiting of the invention. All publications, patent
applications, patents, patent publications and other references
cited herein are incorporated by reference in their entireties for
the teachings relevant to the sentence and/or paragraph in which
the reference is presented.
Nucleotide sequences are presented herein by single strand only, in
the 5' to 3' direction, from left to right, unless specifically
indicated otherwise. Nucleotides and amino acids are represented
herein in the manner recommended by the IUPAC-IUB Biochemical
Nomenclature Commission, or (for amino acids) by either the
one-letter code, or the three letter code, both in accordance with
37 C.F.R. .sctn. 1.822 and established usage.
Except as otherwise indicated, standard methods known to those
skilled in the art may be used for cloning genes, amplifying and
detecting nucleic acids, and the like. Such techniques are known to
those skilled in the art. See, e.g., Sambrook et al., Molecular
Cloning: A Laboratory Manual 2nd Ed. (Cold Spring Harbor, N.Y.,
1989); Ausubel et al, Current Protocols in Molecular Biology (Green
Publishing Associates, Inc. and John Wiley & Sons, Inc., New
York).
Unless the context indicates otherwise, it is specifically intended
that the various features of the invention described herein can be
used in any combination.
Moreover, the present invention also contemplates that in some
embodiments of the invention, any feature or combination of
features set forth herein can be excluded or omitted.
To illustrate, if the specification states that a complex comprises
components A, B and C, it is specifically intended that any of A, B
or C, or a combination thereof, can be omitted and disclaimed
singularly or in any combination.
Definitions
As used in the description of the invention and the appended
claims, the singular forms "a," "an," and "the" are intended to
include the plural forms as well, unless the context clearly
indicates otherwise.
Also as used herein, "and/or" refers to and encompasses any and all
possible combinations of one or more of the associated listed
items, as well as the lack of combinations when interpreted in the
alternative ("or").
The term "about," as used herein when referring to a measurable
value such as an amount of polypeptide, dose, time, temperature,
enzymatic activity or other biological activity and the like, is
meant to encompass variations of +20%, .+-.10%, .+-.5%, .+-.1%,
.+-.0.5%, or even .+-.0.1% of the specified amount.
As used herein, the transitional phrase "consisting essentially of"
(and grammatical variants) is to be interpreted as encompassing the
recited materials or steps and those that do not materially affect
the basic and novel characteristic(s) of the claimed invention.
Thus, the term "consisting essentially of" as used herein should
not be interpreted as equivalent to "comprising."
The term "consists essentially of" (and grammatical variants), as
applied to a polynucleotide sequence of this invention, means a
polynucleotide that consists of both the recited sequence (e.g, SEQ
ID NO) and a total of ten or less (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9,
or 10) additional nucleotides on the 5' and/or 3' ends of the
recited sequence such that the function of the polynucleotide is
not materially altered. The total of ten or less additional
nucleotides includes the total number of additional nucleotides on
both ends added together. The term "materially altered," as applied
to polynucleotides of the invention, refers to an increase or
decrease in ability to inhibit expression of a target mRNA of at
least about 50% or more as compared to the expression level of a
polynucleotide consisting of the recited sequence.
The term "enhance" or "increase" refers to an increase in the
specified parameter of at least about 1.25-fold, 1.5-fold, 2-fold,
3-fold, 4-fold, 5-fold, 6-fold, 8-fold, 10-fold, twelve-fold, or
even fifteen-fold.
The term "inhibit" or "reduce" or grammatical variations thereof as
used herein refers to a decrease or diminishment in the specified
level or activity of at least about 15%, 25%, 35%, 40%, 50%, 60%,
75%, 80%, 90%, 95% or more. In particular embodiments, the
inhibition or reduction results in little or essentially no
detectable activity (at most, an insignificant amount, e.g., less
than about 10% or even 5%).
A "therapeutically effective" amount as used herein is an amount
that provides some improvement or benefit to the subject.
Alternatively stated, a "therapeutically effective" amount is an
amount that will provide some alleviation, mitigation, or decrease
in at least one clinical symptom in the subject (e.g., in the case
of cancer, reduction in tumor burden, prevention of further tumor
growth, prevention of metastasis, or increase in survival time).
Those skilled in the art will appreciate that the therapeutic
effects need not be complete or curative, as long as some benefit
is provided to the subject.
By the terms "treat," "treating," or "treatment of," it is intended
that the severity of the subject's condition is reduced or at least
partially improved or modified and that some alleviation,
mitigation or decrease in at least one clinical symptom is
achieved.
"Prevent" or "preventing" or "prevention" refer to prevention or
delay of the onset of the disorder and/or a decrease in the
severity of the disorder in a subject relative to the severity that
would develop in the absence of the methods of the invention. The
prevention can be complete, e.g., the total absence of cancer in a
subject. The prevention can also be partial, such that the
occurrence or severity of cancer in a subject is less than that
which would have occurred without the present invention.
As used herein, "nucleic acid," "nucleotide sequence," and
"polynucleotide" are used interchangeably and encompass both RNA
and DNA, including cDNA, genomic DNA, mRNA, synthetic (e.g.,
chemically synthesized) DNA or RNA and chimeras of RNA and DNA. The
term polynucleotide, nucleotide sequence, or nucleic acid refers to
a chain of nucleotides without regard to length of the chain. The
nucleic acid can be double-stranded or single-stranded. Where
single-stranded, the nucleic acid can be a sense strand or an
antisense strand. The nucleic acid can be synthesized using
oligonucleotide analogs or derivatives (e.g., inosine or
phosphorothioate nucleotides). Such oligonucleotides can be used,
for example, to prepare nucleic acids that have altered
base-pairing abilities or increased resistance to nucleases. The
present invention further provides a nucleic acid that is the
complement (which can be either a full complement or a partial
complement) of a nucleic acid, nucleotide sequence, or
polynucleotide of this invention. When dsRNA is produced
synthetically less common bases, such as inosine, 5-methylcytosine,
6-methyladenine, hypoxanthine and others can also be used for
antisense, dsRNA, and ribozyme pairing. For example,
polynucleotides that contain C-5 propyne analogues of uridine and
cytidine have been shown to bind RNA with high affinity and to be
potent antisense inhibitors of gene expression. Other
modifications, such as modification to the phosphodiester backbone,
or the 2'-hydroxy in the ribose sugar group of the RNA can also be
made.
An "isolated polynucleotide" is a nucleotide sequence (e.g., DNA or
RNA) that is not immediately contiguous with nucleotide sequences
with which it is immediately contiguous (one on the 5' end and one
on the 3' end) in the naturally occurring genome of the organism
from which it is derived. Thus, in one embodiment, an isolated
nucleic acid includes some or all of the 5' non-coding (e.g.,
promoter) sequences that are immediately contiguous to a coding
sequence. The term therefore includes, for example, a recombinant
DNA that is incorporated into a vector, into an autonomously
replicating plasmid or virus, or into the genomic DNA of a
prokaryote or eukaryote, or which exists as a separate molecule
(e.g., a cDNA or a genomic DNA fragment produced by PCR or
restriction endonuclease treatment), independent of other
sequences. It also includes a recombinant DNA that is part of a
hybrid nucleic acid encoding an additional polypeptide or peptide
sequence. An isolated polynucleotide that includes a gene is not a
fragment of a chromosome that includes such gene, but rather
includes the coding region and regulatory regions associated with
the gene, but no additional genes naturally found on the
chromosome.
The term "isolated" can refer to a nucleic acid, nucleotide
sequence or polypeptide that is substantially free of cellular
material, viral material, and/or culture medium (when produced by
recombinant DNA techniques), or chemical precursors or other
chemicals (when chemically synthesized). Moreover, an "isolated
fragment" is a fragment of a nucleic acid, nucleotide sequence or
polypeptide that is not naturally occurring as a fragment and would
not be found in the natural state, "Isolated" does not mean that
the preparation is technically pure (homogeneous), but it is
sufficiently pure to provide the polypeptide or nucleic acid in a
form in which it can be used for the intended purpose.
An "isolated cell" refers to a cell that is separated from other
components with which it is normally associated in its natural
state. For example, an isolated cell can be a cell in culture
medium and/or a cell in a pharmaceutically acceptable carrier of
this invention. Thus, an isolated cell can be delivered to and/or
introduced into a subject. In some embodiments, an isolated cell
can be a cell that is removed from a subject and manipulated as
described herein ex vivo and then returned to the subject.
The term "fragment," as applied to a polynucleotide, will be
understood to mean a nucleotide sequence of reduced length relative
to a reference nucleic acid or nucleotide sequence and comprising,
consisting essentially of, and/or consisting of a nucleotide
sequence of contiguous nucleotides identical or almost identical
(e.g., 90%, 92%, 95%, 98%, 99% identical) to the reference nucleic
acid or nucleotide sequence. Such a nucleic acid fragment according
to the invention may be, where appropriate, included in a larger
polynucleotide of which it is a constituent. In some embodiments,
such fragments can comprise, consist essentially of, and/or consist
of oligonucleotides having a length of at least about 8, 10, 12,
15, 20, 25, 30, 35, 40, 45, 50, 75, 100, 150, 200, or more
consecutive nucleotides of a nucleic acid or nucleotide sequence
according to the invention.
The term "fragment," as applied to a polypeptide, will be
understood to mean an amino acid sequence of reduced length
relative to a reference polypeptide or amino acid sequence and
comprising, consisting essentially of, and/or consisting of an
amino acid sequence of contiguous amino acids identical or almost
identical (e.g., 90%, 92%, 95%, 98%, 99% identical) to the
reference polypeptide or amino acid sequence. Such a polypeptide
fragment according to the invention may be, where appropriate,
included in a larger polypeptide of which it is a constituent. In
some embodiments, such fragments can comprise, consist essentially
of, and/or consist of peptides having a length of at least about 4,
6, 8, 10, 12, 15, 20, 25, 30, 35, 40, 45, 50, 75, 100, 150, 200, or
more consecutive amino acids of a polypeptide or amino acid
sequence according to the invention.
A "vector" is any nucleic acid molecule for the cloning of and/or
transfer of a nucleic acid into a cell. A vector may be a replicon
to which another nucleotide sequence may be attached to allow for
replication of the attached nucleotide sequence. A "replicon" can
be any genetic element (e.g., plasmid, phage, cosmid, chromosome,
viral genome) that functions as an autonomous unit of nucleic acid
replication in vivo, i.e., capable of replication under its own
control. The term "vector" includes both viral and nonviral (e.g.,
plasmid) nucleic acid molecules for introducing a nucleic acid into
a cell in vitro, ex vivo, and/or in vivo. A large number of vectors
known in the art may be used to manipulate nucleic acids,
incorporate response elements and promoters into genes, etc. For
example, the insertion of the nucleic acid fragments corresponding
to response elements and promoters into a suitable vector can be
accomplished by ligating the appropriate nucleic acid fragments
into a chosen vector that has complementary cohesive termini.
Alternatively, the ends of the nucleic acid molecules may be
enzymatically modified or any site may be produced by ligating
nucleotide sequences (linkers) to the nucleic acid termini. Such
vectors may be engineered to contain sequences encoding selectable
markers that provide for the selection of cells that contain the
vector and/or have incorporated the nucleic acid of the vector into
the cellular genome. Such markers allow identification and/or
selection of host cells that incorporate and express the proteins
encoded by the marker. A "recombinant" vector refers to a viral or
non-viral vector that comprises one or more heterologous nucleotide
sequences (i.e., transgenes e.g., two, three, four, five or more
heterologous nucleotide sequences.
Viral vectors have been used in a wide variety of gene delivery
applications in cells, as well as living animal subjects. Viral
vectors that can be used include, but are not limited to,
retrovirus, lentivirus, adeno-associated virus, poxvirus,
alphavirus, baculovirus, vaccinia virus, herpes virus, Epstein-Barr
virus, and/or adenovirus vectors. Non-viral vectors include, but
are not limited to, plasmids, liposomes, electrically charged
lipids (cytofectins), nucleic acid-protein complexes, and
biopolymers. In addition to a nucleic acid of interest, a vector
may also comprise one or more regulatory regions, and/or selectable
markers useful in selecting, measuring, and monitoring nucleic acid
transfer results (delivery to specific tissues, duration of
expression, etc.).
Vectors may be introduced into the desired cells by methods known
in the art, e.g., transfection, electroporation, microinjection,
transduction, cell fusion, DEAE dextran, calcium phosphate
precipitation, lipofection (lysosome fusion), use of a gene gun, or
a nucleic acid vector transporter (see, e.g., Wu et al., J. Biol.
Chem. 267:963 (1992); Wu et al., J. Biol. Chem. 263:14621 (1988);
and Hartmut et al., Canadian Patent Application No. 2,012,311,
filed Mar. 15, 1990).
In some embodiments, a polynucleotide of this invention can be
delivered to a cell in vivo by lipofection. Synthetic cationic
lipids designed to limit the difficulties and dangers encountered
with liposome-mediated transfection can be used to prepare
liposomes for in vivo transfection of a nucleotide sequence of this
invention (Feigner et al., Proc. Natl. Acad. Sci. USA 84:7413
(1987); Mackey, et al., Proc. Natl. Acad. Sci. USA. 85:8027 (1988);
and Ulmer et al., Science 259:1745 (1993)). The use of cationic
lipids may promote encapsulation of negatively charged nucleic
acids, and also promote fusion with negatively charged cell
membranes (Feigner et al., Science 337:387 (1989)). Particularly
useful lipid compounds and compositions for transfer of nucleic
acids are described in International Patent Publications WO95/18863
and WO96/17823, and in U.S. Pat. No. 5,459,127. The use of
lipofection to introduce exogenous nucleotide sequences into
specific organs in vivo has certain practical advantages. Molecular
targeting of liposomes to specific cells represents one area of
benefit. It is clear that directing transfection to particular cell
types would be particularly preferred in a tissue with cellular
heterogeneity, such as pancreas, liver, kidney, and the brain.
Lipids may be chemically coupled to other molecules for the purpose
of targeting (Mackey, et al., 1988, supra). Targeted peptides,
e.g., hormones or neurotransmitters, and proteins such as
antibodies, or non-peptide molecules can be coupled to liposomes
chemically.
In various embodiments, other molecules can be used for
facilitating delivery of a nucleic acid in vivo, such as a cationic
oligopeptide (e.g., WO95/21931), peptides derived from nucleic acid
binding proteins (e.g., WO96/25508), and/or a cationic polymer
(e.g., WO95/21931).
It is also possible to introduce a vector in vivo as naked nucleic
acid (see U.S. Pat. Nos. 5,693,622, 5,589,466 and 5,580,859).
Receptor-mediated nucleic acid delivery approaches can also be used
(Curiel et al., Hum. Gene Ther. 3:147 (1992); Wu et al., J. Biol.
Chem. 262:4429 (1987)).
As used herein, the terms "protein" and "polypeptide" are used
interchangeably and encompass both peptides and proteins, unless
indicated otherwise.
A "fusion protein" is a polypeptide produced when two heterologous
nucleotide sequences or fragments thereof coding for two (or more)
different polypeptides not found fused together in nature are fused
together in the correct translational reading frame. Illustrative
fusion polypeptides include fusions of a polypeptide of the
invention (or a fragment thereof) to all or a portion of
glutathione-S-transferase, maltose-binding protein, or a reporter
protein (e.g., Green Fluorescent Protein, .beta.-glucuronidase,
.beta.-galactosidase, luciferase, etc.), hemagglutinin, c-myc, FLAG
epitope, etc.
By the term "express" or "expression" of a polynucleotide coding
sequence, it is meant that the sequence is transcribed, and
optionally, translated. Typically, according to the present
invention, expression of a coding sequence of the invention will
result in production of the polypeptide of the invention. The
entire expressed polypeptide or fragment can also function in
intact cells without purification.
As used herein, the term "gene" refers to a nucleic acid molecule
capable of being used to produce mRNA, antisense RNA, miRNA, and
the like. Genes may or may not be capable of being used to produce
a functional protein. Genes can include both coding and non-coding
regions (e.g., introns, regulatory elements, promoters, enhancers,
termination sequences and 5' and 3' untranslated regions). A gene
may be "isolated" by which is meant a nucleic acid that is
substantially or essentially free from components normally found in
association with the nucleic acid in its natural state. Such
components include other cellular material, culture medium from
recombinant production, and/or various chemicals used in chemically
synthesizing the nucleic acid.
As used herein, "complementary" polynucleotides are those that are
capable of base pairing according to the standard Watson-Crick
complementarity rules. Specifically, purines will base pair with
pyrimidines to form a combination of guanine paired with cytosine
(G:C) and adenine paired with either thymine (A:T) in the case of
DNA, or adenine paired with uracil (A:U) in the case of RNA. For
example, the sequence "A-G-T" binds to the complementary sequence
"T-C-A." It is understood that two polynucleotides may hybridize to
each other even if they are not completely complementary to each
other, provided that each has at least one region that is
substantially complementary to the other.
The terms "complementary" or "complementarily," as used herein,
refer to the natural binding of polynucleotides under permissive
salt and temperature conditions by base-pairing. Complementarity
between two single-stranded molecules may be "partial," in which
only some of the nucleotides bind, or it may be complete when total
complementarity exists between the single stranded molecules. The
degree of complementarily between nucleic acid strands has
significant effects on the efficiency and strength of hybridization
between nucleic acid strands.
As used herein, the terms "substantially complementary" or
"partially complementary" mean that two nucleic acid sequences are
complementary at least about 50%, 60%, 70%, 80% or 90% of their
nucleotides. In some embodiments, the two nucleic acid sequences
can be complementary at least at 85%, 90%, 95%, 96%, 97%, 98%, 99%
or more of their nucleotides. The terms "substantially
complementary" and "partially complementary" can also mean that two
nucleic acid sequences can hybridize under high stringency
conditions and such conditions are well known in the art.
As used herein, "heterologous" refers to a nucleic acid sequence
that either originates from another species or is from the same
species or organism but is modified from either its original form
or the form primarily expressed in the cell. Thus, a nucleotide
sequence derived from an organism or species different from that of
the cell into which the nucleotide sequence is introduced, is
heterologous with respect to that cell and the cell's descendants.
In addition, a heterologous nucleotide sequence includes a
nucleotide sequence derived from and inserted into the same
natural, original cell type, but which is present in a non-natural
state, e.g., a different copy number, and/or under the control of
different regulatory sequences than that found in nature.
As used herein, the terms "contacting," "introducing" and
"administering" are used interchangeably, and refer to a process by
which dsRNA of the present invention or a nucleic acid molecule
encoding a dsRNA of this invention is delivered to a cell, in order
to inhibit or alter or modify expression of a target gene. The
dsRNA may be administered in a number of ways, including, but not
limited to, direct introduction into a cell (i.e., intracellularly)
and/or extracellular introduction into a cavity, interstitial
space, or into the circulation of the organism.
"Introducing" in the context of a cell or organism means presenting
the nucleic acid molecule to the organism and/or cell in such a
manner that the nucleic acid molecule gains access to the interior
of a cell. Where more than one nucleic acid molecule is to be
introduced these nucleic acid molecules can be assembled as part of
a single polynucleotide or nucleic acid construct, or as separate
polynucleotide or nucleic acid constructs, and can be located on
the same or different nucleic acid constructs. Accordingly, these
polynucleotides can be introduced into cells in a single
transformation event or in separate transformation events. Thus,
the term "transformation" as used herein refers to the introduction
of a heterologous nucleic acid into a cell. Transformation of a
cell may be stable or transient.
"Transient transformation" in the context of a polynucleotide means
that a polynucleotide is introduced into the cell and does not
integrate into the genome of the cell.
By "stably introducing" or "stably introduced" in the context of a
polynucleotide introduced into a cell, it is intended that the
introduced polynucleotide is stably incorporated into the genome of
the cell, and thus the cell is stably transformed with the
polynucleotide.
"Stable transformation" or "stably transformed" as used herein
means that a nucleic acid molecule is introduced into a cell and
integrates into the genome of the cell. As such, the integrated
nucleic acid molecule is capable of being inherited by the progeny
thereof, more particularly, by the progeny of multiple successive
generations. "Genome" as used herein includes the nuclear and
mitochondrial genome, and therefore includes integration of the
nucleic acid into, for example, the mitochondrial genome. Stable
transformation as used herein can also refer to a transgene that is
maintained extrachromasomally, for example, as a
minichromosome.
Transient transformation may be detected by, for example, an
enzyme-linked immunosorbent assay (ELISA) or Western blot, which
can detect the presence of a peptide or polypeptide encoded by one
or more transgene introduced into an organism. Stable
transformation of a cell can be detected by, for example, a
Southern blot hybridization assay of genomic DNA of the cell with
nucleic acid sequences which specifically hybridize with a
nucleotide sequence of a transgene introduced into an organism.
Stable transformation of a cell can be detected by, for example, a
Northern blot hybridization assay of RNA of the cell with nucleic
acid sequences which specifically hybridize with a nucleotide
sequence of a transgene introduced into an organism. Stable
transformation of a cell can also be detected by, e.g., a
polymerase chain reaction (PCR) or other amplification reactions as
are well known in the art, employing specific primer sequences that
hybridize with target sequence(s) of a transgene, resulting in
amplification of the transgene sequence, which can be detected
according to standard methods. Transformation can also be detected
by direct sequencing and/or hybridization protocols well known in
the art.
Embodiments of the invention are directed to expression cassettes
designed to express the nucleic acids of the present invention. As
used herein, "expression cassette" means a nucleic acid molecule
having at least a control sequence operably linked to a nucleotide
sequence of interest. In this manner, for example, promoters in
operable interaction with the nucleotide sequences for the siRNAs
of the invention are provided in expression cassettes for
expression in an organism or cell.
As used herein, the term "promoter" refers to a region of a
nucleotide sequence that incorporates the necessary signals for the
efficient expression of a coding sequence. This may include
sequences to which an RNA polymerase binds, but is not limited to
such sequences and can include regions to which other regulatory
proteins bind together with regions involved in the control of
protein translation and can also include coding sequences.
Furthermore, a "promoter" of this invention is a promoter capable
of initiating transcription in a cell of an organism. Such
promoters include those that drive expression of a nucleotide
sequence constitutively, those that drive expression when induced,
and those that drive expression in a tissue- or
developmentally-specific manner, as these various types of
promoters are known in the art.
For purposes of the invention, the regulatory regions (i.e.,
promoters, transcriptional regulatory regions, and translational
termination regions) can be native/analogous to the organism or
cell and/or the regulatory regions can be native/analogous to the
other regulatory regions. Alternatively, the regulatory regions may
be heterologous to the organism or cell and/or to each other (i.e.,
the regulatory regions). Thus, for example, a promoter can be
heterologous when it is operably linked to a polynucleotide from a
species different from the species from which the polynucleotide
was derived. Alternatively, a promoter can also be heterologous to
a selected nucleotide sequence if the promoter is from the
same/analogous species from which the polynucleotide is derived,
but one or both (i.e., promoter and polynucleotide) are
substantially modified from their original form and/or genomic
locus, or the promoter is not the native promoter for the operably
linked polynucleotide.
The choice of promoters to be used depends upon several factors,
including, but not limited to, cell- or tissue-specific expression,
desired expression level, efficiency, inducibility and
selectability. For example, where expression in a specific tissue
or organ is desired, a tissue-specific promoter can be used. In
contrast, where expression in response to a stimulus is desired, an
inducible promoter can be used. Where continuous expression is
desired throughout the cells of an organism, a constitutive
promoter can be used. It is a routine matter for one of skill in
the art to modulate the expression of a nucleotide sequence by
appropriately selecting and positioning promoters and other
regulatory regions relative to that sequence.
In addition to the promoters described above, the expression
cassette also can include other regulatory sequences. As used
herein, "regulatory sequences" means nucleotide sequences located
upstream (5' non-coding sequences), within or downstream (3'
non-coding sequences) of a coding sequence, and which influence the
transcription, RNA processing or stability, or translation of the
associated coding sequence. Regulatory sequences include, but are
not limited to, enhancers, introns, translation leader sequences
and polyadenylation signal sequences.
The expression cassette also can optionally include a
transcriptional and/or translational termination region (i.e.,
termination region) that is functional in the organism. A variety
of transcriptional terminators are available for use in expression
cassettes and are responsible for the termination of transcription
beyond the transgene and correct mRNA polyadenylation. The
termination region may be native to the transcriptional initiation
region, may be native to the operably linked nucleotide sequence of
interest, may be native to the host, or may be derived from another
source (i.e., foreign or heterologous to the promoter, the
nucleotide sequence of interest, the host, or any combination
thereof).
A signal sequence can be operably linked to nucleic acids of the
present invention to direct the nucleotide sequence into a cellular
compartment. In this manner, the expression cassette will comprise
a nucleotide sequence encoding the siRNA operably linked to a
nucleic acid sequence for the signal sequence. The signal sequence
may be operably linked at the N- or C-terminus of the siRNA.
Regardless of the type of regulatory sequence(s) used, they can be
operably linked to the nucleotide sequence of the siRNA. As used
herein, "operably linked" means that elements of a nucleic acid
construct such as an expression cassette are configured so as to
perform their usual function. Thus, regulatory or control sequences
(e.g., promoters) operably linked to a nucleotide sequence of
interest are capable of effecting expression of the nucleotide
sequence of interest. The control sequences need not be contiguous
with the nucleotide sequence of interest, so long as they function
to direct the expression thereof. Thus, for example, intervening
untranslated, yet transcribed, sequences can be present between a
promoter and a coding sequence, and the promoter sequence can still
be considered "operably linked" to the coding sequence. A
nucleotide sequence of the present invention (i.e., a siRNA) can be
operably linked to a regulatory sequence, thereby allowing its
expression in a cell and/or subject.
The expression cassette also can include a nucleotide sequence for
a selectable marker, which can be used to select a transformed
organism or cell. As used herein, "selectable marker" means a
nucleic acid that when expressed imparts a distinct phenotype to
the organism or cell expressing the marker and thus allows such
transformed organisms or cells to be distinguished from those that
do not have the marker. Such a nucleic acid may encode either a
selectable or screenable marker, depending on whether the marker
confers a trait that can be selected for by chemical means, such as
by using a selective agent (e.g., an antibiotic or the like), or on
whether the marker is simply a trait that one can identify through
observation or testing, such as by screening (. Of course, many
examples of suitable selectable markers are known in the art and
can be used in the expression cassettes described herein.
In some embodiments of the present invention, the expression
cassette can comprise an expression control sequence operatively
linked to a nucleotide sequence that is a template for one or both
strands of the dsRNA. In further embodiments, a promoter can flank
either end of the template nucleotide sequence, wherein the
promoters drive expression of each individual DNA strand, thereby
generating two complementary (or substantially complementary) RNAs
that hybridize and form the dsRNA. In alternative embodiments, the
nucleotide sequence is transcribed into both strands of the dsRNA
on one transcription unit, wherein the sense strand is transcribed
from the 5' end of the transcription unit and the antisense strand
is transcribed from the 3' end, wherein the two strands are
separated by about 3 to about 500 basepairs, and wherein after
transcription, the RNA transcript folds on itself to form a short
hairpin RNA (shRNA) molecule.
As used herein "sequence identity" refers to the extent to which
two optimally aligned polynucleotide or polypeptide sequences are
invariant throughout a window of alignment of components, e.g.,
nucleotides or amino acids. "Identity" can be readily calculated by
known methods including, but not limited to, those described in:
Computational Molecular Biology (Lesk, A. M., ed.) Oxford
University Press, New York (1988); Biocomputing: Informatics and
Genome Projects (Smith, D. W., ed.) Academic Press, New York
(1993); Computer Analysis of Sequence Data, Part I (Griffin, A. M.,
and Griffin, H. G., eds.) Humana Press, N.J. (1994); Sequence
Analysis in Molecular Biology (von Heinje, G., ed.) Academic Press
(1987); and Sequence Analysis Primer (Gribskov, M. and Devereux,
J., eds.) Stockton Press, New York (1991).
As used herein, the term "substantially identical" or
"corresponding to" means that two nucleic acid sequences have at
least 60%, 70%, 80% or 90% sequence identity. In some embodiments,
the two nucleic acid sequences can have at least 85%, 90%, 95%,
96%, 97%, 98%, 99% or 100% of sequence identity.
An "identity fraction" for aligned segments of a test sequence and
a reference sequence is the number of identical components which
are shared by the two aligned sequences divided by the total number
of components in reference sequence segment, i.e., the entire
reference sequence or a smaller defined part of the reference
sequence.
As used herein, the term "percent sequence identity" or "percent
identity" refers to the percentage of identical nucleotides in a
linear polynucleotide sequence of a reference ("query")
polynucleotide molecule (or its complementary strand) as compared
to a test ("subject") polynucleotide molecule (or its complementary
strand) when the two sequences are optimally aligned (with
appropriate nucleotide insertions, deletions, or gaps totaling less
than 20 percent of the reference sequence over the window of
comparison). In some embodiments, "percent identity" can refer to
the percentage of identical amino acids in an amino acid
sequence.
Optimal alignment of sequences for aligning a comparison window are
well known to those skilled in the art and may be conducted by
tools such as the local homology algorithm of Smith and Waterman,
the homology alignment algorithm of Needleman and Wunsch, the
search for similarity method of Pearson and Lipman, and optionally
by computerized implementations of these algorithms such as GAP,
BESTFIT, FASTA, and TFASTA available as part of the GCG.RTM.
Wisconsin Package.RTM. (Accelrys Inc., Burlington, Mass.). Percent
sequence identity is represented as the identity fraction
multiplied by 100. The comparison of one or more polynucleotide
sequences may be to a full-length polynucleotide sequence or a
portion thereof, or to a longer polynucleotide sequence. For
purposes of this invention "percent identity" may also be
determined using BLASTX version 2.0 for translated nucleotide
sequences and BLASTN version 2.0 for polynucleotide sequences.
The percent of sequence identity can be determined using the "Best
Fit" or "Gap" program of the Sequence Analysis Software Package.TM.
(Version 10; Genetics Computer Group, Inc., Madison, Wis.). "Gap"
utilizes the algorithm of Needleman and Wunsch (Needleman and
Wunsch, J Mol. Biol. 48:443-453, 1970) to find the alignment of two
sequences that maximizes the number of matches and minimizes the
number of gaps. "BestFit" performs an optimal alignment of the best
segment of similarity between two sequences and inserts gaps to
maximize the number of matches using the local homology algorithm
of Smith and Waterman (Smith and Waterman, Adv. Appl. Math.,
2:482-489, 1981, Smith et al., Nucleic Acids Res. 11:2205-2220,
1983).
Useful methods for determining sequence identity are also disclosed
in Guide to Huge Computers (Martin J. Bishop, ed., Academic Press,
San Diego (1994)), and Carillo, H., and Lipton, D., (Applied Math
48:1073(1988)). More particularly, preferred computer programs for
determining sequence identity include but are not limited to the
Basic Local Alignment Search Tool (BLAST) programs which are
publicly available from National Center Biotechnology Information
(NCBI) at the National Library of Medicine, National Institute of
Health, Bethesda, Md. 20894; see BLAST Manual, Altschul et al.,
NCBI, NLM, NIH; (Altschul et al., J. Mol. Biol. 215:403-410
(1990)); version 2.0 or higher of BLAST programs allows the
introduction of gaps (deletions and insertions) into alignments;
for peptide sequence BIASTX can be used to determine sequence
identity; and, for polynucleotide sequence BLASTN can be used to
determine sequence identity.
As used herein, "RNAi" or "RNA interference" refers to the process
of sequence-specific post-transcriptional gene silencing, mediated
by double-stranded RNA (dsRNA). As used herein, "dsRNA" refers to
RNA that is partially or completely double stranded. Double
stranded RNA is also referred to as small interfering RNA (siRNA),
small interfering nucleic acid (siNA), microRNA (miRNA), and the
like. In the RNAi process, dsRNA comprising a first (antisense)
strand that is complementary to a portion of a target gene and a
second (sense) strand that is fully or partially complementary to
the first antisense strand is introduced into an organism. After
introduction into the organism, the target gene-specific dsRNA is
processed into relatively small fragments (siRNAs) and can
subsequently become distributed throughout the organism, leading to
a loss-of-function mutation having a phenotype that, over the
period of a generation, may come to closely resemble the phenotype
arising from a complete or partial deletion of the target gene.
MicroRNAs (miRNAs) are non-protein coding RNAs, generally of
between about 18 to about 25 nucleotides in length. These miRNAs
direct cleavage in trans of target transcripts, negatively
regulating the expression of genes involved in various regulation
and development pathways (Bartel, Cell, 116:281-297 (2004); Zhang
et al. Dev. Biol. 289:3-16 (2006)). As such, miRNAs have been shown
to be involved in different aspects of growth and development as
well as in signal transduction and protein degradation. Since the
first miRNAs were discovered in plants (Reinhart et al. Genes Dev.
16:1616-1626 (2002), Park et al. Curr. Biol. 12:1484-1495 (2002))
many hundreds have been identified. Many microRNA genes (MIR genes)
have been identified and made publicly available in a database
(miRBase; microrna.sanger.ac.uk/sequences). miRNAs are also
described in U.S. Patent Publications 2005/0120415 and
2005/144669A1, the entire contents of which are incorporated by
reference herein.
Genes encoding miRNAs yield primary miRNAs (termed a "pri-miRNA")
of 70 to 300 bp in length that can form imperfect stem-loop
structures. A single pri-miRNA may contain from one to several
miRNA precursors. In animals, pri-miRNAs are processed in the
nucleus into shorter hairpin RNAs of about 65 nt (pre-miRNAs) by
the RNaseIII enzyme Drosha and its cofactor DGCR8/Pasha. The
pre-miRNA is then exported to the cytoplasm, where it is further
processed by another RNaseIII enzyme, Dicer, releasing a
miRNA/miRNA* duplex of about 22 nt in size. Many reviews on
microRNA biogenesis and function are available, for example, see.
Bartel Cell 116:281-297 (2004), Murchison et al. Curr. Opin. Cell
Biol. 16:223-229 (2004), Dugas et al. Curr. Opin. Plant Biol.
7:512-520 (2004) and Kim Nature Rev. Mol. Cell Biol. 6:376-385
(2005).
RNA Molecules
The present invention is based on the identification of RNA
molecules that inhibit expression of mutant KRAS sequences while
sparing expression of WT KRAS. Accordingly, one aspect of the
invention relates to a double stranded RNA molecule comprising an
antisense strand and a sense strand, wherein the nucleotide
sequence of the antisense strand is complementary to a region of
the nucleotide sequence of a synthetic human KRAS gene that
contains the missense mutations G12C, G12D, and G13D or the
missense mutations G12C, G12V, and G13D, the region consisting
essentially of about 18 to about 25 consecutive nucleotides;
wherein the double stranded RNA molecule inhibits expression of a
mutant human KRAS gene comprising one or more of the missense
mutations G12C, G12D, and G13D and minimally inhibits expression of
wild-type human KRAS. The region of the KRAS gene targeted by the
RNA molecule comprises the nucleotides encoding residues 12 and 13.
The RNA molecules provide decreased expression of mutant KRAS in a
cell as compared to a wild-type variety of the cell (e.g., a
control cell or nontransformed cell). In some embodiments,
expression of mutant KRAS is inhibited by at least about 50%, e.g.,
at least about 50%, 60%, 70%, 80%, 90%, 95%, or more.
A human KRAS gene containing the missense mutations G12C, G12D, and
G13D or the missense mutations G12C, G12V, and G13D does not exist
in nature. Examples of a region of such artificial gene sequences
include SEQ ID NOS:37 and 38, with the mutations relative to the
corresponding WT KRAS sequence (SEQ ID NO:39) underlined.
TABLE-US-00001 SEQ ID NO: 37
ACTGAATATAAACTTGTGGTAGTTGGAGCTTATGACGTAGGCAAGAGTGC CTTGACGATACAG
SEQ ID NO: 38 ACTGAATATAAACTIGTGGTAGTTGGAGCTTTTGACGTAGGCAAGAGTGC
CTTGACGATACAG SEQ ID NO: 39
ACTGAATATAAACTTGTGGTAGTTGGAGCTGGTGGCGTAGGCAAGAGTGC
CTTGACGATACAG
The double stranded RNA molecule can comprise, consist essentially
of, or consist of about 18 to about 25 nucleotides (e.g., 18, 19,
20, 21, 22, 23, 24, or 25 or any range therein). Additional
nucleotides can be added at the 3' end, the 5' end or both the 3'
and 5' ends to facilitate manipulation of the RNA molecule but that
do not materially affect the basic characteristics or function of
the double stranded RNA molecule in RNA interference (RNAi).
Additionally, one or two nucleotides can be deleted from one or
both ends of any of the sequences disclosed herein that do not
materially affect the basic characteristics or function of the
double stranded RNA molecule in RNAi. The term "materially affect"
as used herein refers to a change in the ability to inhibit
expression of the protein encoded by the mRNA (e.g., WF KRAS) by no
more than about 50%, e.g., no more than about 50%, 45%, 40%, 35%,
30%, 25%, 20%, 15%, 10%, or less. Such additional nucleotides can
be nucleotides that extend the complementarity of the antisense
strand along the target sequence and/or such nucleotides can be
nucleotides that facilitate manipulation of the RNA molecule or a
nucleic acid molecule encoding the RNA molecule, as would be known
to one of skill in the art. For example, a TT overhang at the 3'
end may be present, which is used to stabilize the siRNA duplex and
does not affect the specificity of the siRNA.
The dsRNA of the invention may optionally comprise a single
stranded overhang at either or both ends. The double-stranded
structure may be formed by a single self-complementary RNA strand
(i.e., forming a hairpin loop) or two complementary RNA strands.
RNA duplex formation may be initiated either inside or outside the
cell. When the dsRNA of the invention forms a hairpin loop, it may
optionally comprise an intron and/or a nucleotide spacer, which is
a stretch of nucleotides between the complementary RNA strands, to
stabilize the hairpin sequence in cells. The RNA may be introduced
in an amount that allows delivery of at least one copy per cell.
Higher doses of double-stranded material may yield more effective
inhibition.
In particular embodiments, the present invention provides double
stranded RNA containing a nucleotide sequence that is fully
complementary to a region of the target gene for inhibition.
However, it is to be understood that 100% complementarity between
the antisense strand of the double stranded RNA molecule and the
target sequence is not required to practice the present invention.
Thus, sequence variations that might be expected due to genetic
mutation, strain polymorphism, or evolutionary divergence can be
tolerated. RNA sequences with insertions, deletions, and single
point mutations relative to the target sequence may also be
effective for inhibition.
In certain embodiments, the nucleotide sequence of the antisense
strand contains at least 3 mismatches with the nucleotide sequence
of wild-type human KRAS such that the RNA molecule does not target
WT KRAS and only minimally inhibits expression of WT KRAS. As used
herein, "minimally inhibits expression" means that expression of
the protein encoded by the mRNA WT KRAS) is inhibited by no more
than about 50%, e.g., no more than about 50%, 45%, 40%, 35%, 30%,
25%, 20%, 15%, 10%, or less.
In certain embodiments, the nucleotide sequence of the antisense
strand contains no more than 2 mismatches with the nucleotide
sequence of a mutant human KRAS gene comprising one or more of the
missense mutations G12C, G12D, G12V, and G13D. In some embodiments,
the nucleotide sequence of the antisense strand contains at least 3
mismatches with the nucleotide sequence of wild-type human KRAS and
contains no more than 2 mismatches with the nucleotide sequence of
a mutant human KRAS gene comprising one or more of the missense
mutations G12C, G12D, G12V, and G13D.
In some embodiments, the nucleotide sequence of the sense strand
comprises a nucleotide sequence that is at least about 80%
identical to the nucleotide sequence of any of SEQ ID NOS:1-9,
e.g., at least about 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%,
97%, 98% 99%, or more identical to the nucleotide sequence of any
of SEQ ID NOS:1-9. In some embodiments, the nucleotide sequence of
the sense strand comprises, consists essentially of, or consist of
the nucleotide sequence of any of SEQ ID NOS:1.-9.
TABLE-US-00002 SEQ ID NO: 1 GAGCUUAUGACGUAGGCAA SEQ ID NO: 2
AGUUGGAGCUUAUGACGUA SEQ ID NO: 3 GGUAGUUGGAGCUUAUGAC SEQ ID NO: 4
GUAGUUGGAGCUUAUGACG SEQ ID NO: 5 UAGUUGGAGCUUAUGACGU SEQ ID NO: 6
GUUGGAGCUUAUGACGUAG SEQ ID NO: 7 UUGGAGCUUAUGACGUAGG SEQ ID NO: 8
UGGAGCUUAUGACGUAGGC SEQ ID NO: 9 GGAGCUUAUGACGUAGGCA
In some embodiments, the nucleotide sequence of the antisense
strand comprises a nucleotide sequence that is at least about 80%
identical to the nucleotide sequence of any of SEQ ID NOS:19-27,
e.g., at least about 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%,
97%, 98%, 99%, or more identical to the nucleotide sequence of any
of SEQ ID NOS: 19-27. In some embodiments, the nucleotide sequence
of the antisense strand comprises, consists essentially of, or
consist of the nucleotide sequence of any of SEQ ID NOS: 19-27.
TABLE-US-00003 SEQ ID NO: 19 UUGCCUACGUCAUAAGCUC SEQ ID NO: 20
UACGUCAUAAGCUCCAACU SEQ ID NO: 21 GUCAUAAGCUCCAACUACC SEQ ID NO: 22
CGUCAUAAGCUCCAACUAC SEQ ID NO: 23 ACGUCAUAAGCUCCAACUA SEQ ID NO: 24
CUACGUCAUAAGCUCCAAC SEQ ID NO: 25 CCUACGUCAUAAGCUCCAA SEQ ID NO: 26
GCCUACGUCAUAAGCUCCA SEQ ID NO: 27 UGCCUACGUCAUAAGCUCC
In some embodiments, one or both of the sense strand and the
antisense strand comprises a TT overhang at the 3' end. Thus, in
some embodiments, the sense strand comprises a nucleotide sequence
that is at least about 80% identical to the nucleotide sequence of
any of SEQ ID NOS:10-18, e.g., at least about 80%, 85%, 90%, 91%,
92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or more identical to the
nucleotide sequence of any of SEQ ID NOS: 10-18, In some
embodiments, the nucleotide sequence of the sense strand comprises,
consists essentially of, or consist of the nucleotide sequence of
any of SEQ ID NOS: 10-18.
TABLE-US-00004 SEQ ID NO: 10 GAGCUUAUGACGUAGGCAAdTdT SEQ ID NO: 11
AGUUGGAGCUUAUGACGUAdTdT SEQ ID NO: 12 GGUAGUUGGAGCUUAUGACdTdT SEQ
ID NO: 13 GUAGUUGGAGCUUAUGACGdTdT SEQ ID NO: 14
UAGUUGGAGCUUAUGACGUdTdT SEQ ID NO: 15 GUUGGAGCUUAUGACGUAGdTdT SEQ
ID NO: 16 UUGGAGCUUAUGACGUAGGdTdT SEQ ID NO: 17
UGGAGCUUAUGACGUAGGCdTdT SEQ ID NO: 18 GGAGCUUAUGACGUAGGCAdTdT
In some embodiments, the nucleotide sequence of the antisense
strand comprise a nucleotide sequence that is at least about 80%
identical to the nucleotide sequence of any of SEQ ID NOS:28-36,
e.g., at least about 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%,
97%, 98%, 99%, or more identical to the nucleotide sequence of any
of SEQ ID NOS: 28-36. In some embodiments, the nucleotide sequence
of the antisense strand comprises, consists essentially of, or
consist of the nucleotide sequence of any of SEQ ID NOS: 28-36.
TABLE-US-00005 SEQ ID NO: 28 UUGCCUACGUCAUAAGCUCdTdT SEQ ID NO: 29
UACGUCAUAAGCUCCAACUdTdT SEQ ID NO: 30 GUCAUAAGCUCCAACUACCdTdT SEQ
ID NO: 31 CGUCAUAAGCUCCAACUACdTdT SEQ ID NO: 32
ACGUCAUAAGCUCCAACUAdTdT SEQ ID NO: 33 CUACGUCAUAAGCUCCAACdTdT SEQ
ID NO: 34 CCUACGUCAUAAGCUCCAAdTdT SEQ ID NO: 35
GCCUACGUCAUAAGCUCCAdTdT SEQ ID NO: 36 UGCCUACGUCAUAAGCUCCdTdT
In some embodiments of this invention, the sense strand of the
double stranded RNA molecule can be fully complementary to the
antisense strand or the sense strand can be substantially
complementary or partially complementary to the antisense strand.
By substantially or partially complementary is meant that the sense
strand and the antisense strand can be mismatched at about 1, 2, 3,
4, 5, 6, 7, 8, 9, or 10 nucleotide pairings. Such mismatches can be
introduced into the sense strand sequence, e.g., near the 3' end,
to enhance processing of the double stranded RNA molecule by Dicer,
to duplicate a pattern of mismatches in a siRNA molecule inserted
into a chimeric nucleic acid molecule or artificial microRNA
precursor molecule of this invention, and the like, as would be
known to one of skill in the art. Such modification will weaken the
base pairing at one end of the duplex and generate strand
asymmetry, therefore enhancing the chance of the antisense strand,
instead of the sense strand, being processed and silencing the
intended gene (Geng and Ding "Double-mismatched siRNAs enhance
selective gene silencing of a mutant ALS-causing Allelel" Acta
Pharmacol. Sin. 29:211-216 (2008), Schwarz et al. "Asymmetry in the
assembly of the RNAi enzyme complex" Cell 115:199-208 (2003)).
The double stranded RNA molecule of the invention may be in the
form of any type of RNA interference molecule known in the art. In
some embodiments, the double stranded RNA molecule is a small
interfering RNA (siRNA) molecule. In other embodiments, the double
stranded RNA molecule is a short hairpin RNA (shRNA) molecule. In
other embodiments, the double stranded RNA molecule is part of a
microRNA precursor molecule.
Antisense Oligonucleotides
One aspect of the invention relates to an antisense oligonucleotide
(ASO) targeted to a synthetic human KRAS mRNA that encodes the
missense mutations G12C, G12D, and G13D, wherein the ASO is 16-25
nucleotides in length and comprises or consists essentially of the
sequence TCTTGCCTACGTCATA (SEQ ID NO:114). In some embodiments, the
ASO is 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 nucleotides in
length or any range therein. In some embodiments, the ASO is 20,
21, or 22 nucleotides in length. In some embodiments, the ASO is 20
nucleotides in length. In certain embodiments, at least 80% of the
unspecified nucleotides in the ASO are complementary to a wild-type
human KRAS gene, e.g., at least 80%, 85%, 90%, 91%, 92%, 93%, 94%,
95%, 96%, 97%, 98%, or 99%. In certain embodiments, at least 80% of
the unspecified nucleotides in the ASO are complementary to a
mutant human KRAS gene, e.g., at least 80%, 85%, 90%, 91%, 92%,
93%, 94%, 95%, 96%, 97%, 98%, or 99%. In certain embodiments, the
ASO is 17-25 nucleotides in length and comprises or consists
essentially of the sequence CTCTTGCCTACGTCATA (SEQ ID NO:121),
18-25 nucleotides in length and ACTCTTGCCTACGTCATA (SEQ ID NO:122),
or 19-25 nucleotides in length and CACTCTTGCCTACGTCATA (SEQ ID
NO:123).
In some embodiments, the ASO comprises, consists essentially of, or
consists of the sequence CACTCTTGCCTACGTCATAA (SEQ ID NO:115) or a
sequence at least 90% identical thereto, e.g., at least 90%, 91%,
92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical. In some
embodiments, the ASO comprises, consists essentially of, or
consists of the sequence GCACTCTTGCCTACGTCATA (SEQ NO:116) or a
sequence at least 90% identical thereto, e.g., at least 90%, 91%,
92%. 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical.
The ASO may be comprised of deoxyribonucleotides,
ribonucleotides,or a combination thereof.
In some embodiments, the ASO comprises at least one non-naturally
occurring chemical modification. In certain embodiments, at least
1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, or
19 of the nucleotide linkages are chemically modified. In some
embodiments, the ASO comprises at least one phosphorothioate
linkage. In some embodiments, the ASO comprises 1, 2, 3, 4, 5, 6,
7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, or 19 phosphorothioate
linkages. In some embodiments, the ASO comprises all
phosphorothioate linkages.
In certain embodiments, at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11,
12, 13, 14, 15, 16, 17, 18, or 19 of the nucleotides are chemically
modified. In some embodiments, the ASO comprises at least one
modified nucleotide at or near the 5' end and/or the 3' end, e.g.,
within 5 nucleotides of 5' end and/or the 3' end, e.g., at least 1,
2, 3, 4, or 5 modified nucleotides. In some embodiments, the ASO
comprises at least 3 modified nucleotides at each of the 5' end and
the 3' end, e.g., at least 4 or at least 5. In some embodiments, at
least one of the modified nucleotides is a 2'-O-methoxyethyl
(2'-MOE)-modified nucleotide. In some embodiments, all of the
modified nucleotides is a 2'-MOE-modified nucleotide. In some
embodiments, the ASO comprises at least 3 2'-MOE-modified
nucleotides at each of the 5' end and/or the 3' end, e.g., at least
4 or at least 5.
In some embodiments, the ASO comprises, consists essentially of, or
consists of a sequence selected from:
TABLE-US-00006 (SEQ ID NO: 68) a)
C*A*C*T*C*T*T*G*C*C*T*A*C*G*T*C*A*T*A*A; or b) (SEQ ID NO: 69)
G*C*A*C*T*C*T*T*G*C*C*T*A*C*G*T*C*A*T*A;
wherein * indicates a phosphorothioate linkage and bold indicates a
2'-MOE-modified nucleotide. In some embodiments, the ASO comprises,
consists essentially of, or consists of a sequence at least 90%
identical to one of SEQ ID NO:68 and SEQ ID NO:69, e.g., at least
90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical.
Another aspect of the invention relates to an ASO targeted to a
naturally-occurring human KRAS mRNA encoding a mutation selected
from G12C, G12D, G12V, and G13D, wherein the ASO is 16-25
nucleotides in length and comprises or consists essentially of a
sequence selected from:
a) TCTTGCCTACGCCACA (SEQ ID NO:117) targeted to a human KRAS mRNA
encoding a G12C mutation;
b) TCTTGCCTACGCCATC (SEQ ID NO:118) targeted to a human KRAS mRNA
encoding a G12D mutation;
c) TCTTGCCTACGCCAAC (SEQ ID NO:119) targeted to a human KRAS mRNA
encoding a G12V mutation;
d) TCTTGCCTACGTCACC (SEQ ID NO:120) targeted to a human KRAS mRNA
encoding a G-13D mutation; or
e) a sequence at least 90% identical to any one of a) to d);
wherein the antisense oligonucleotide comprises at least one
non-naturally occurring chemical modification.
In some embodiments, the ASO is at least 90%, 91%, 92%, 93%, 94%,
95%, 96%, 97%, 98%, or 99% identical to one of SEQ ID
NOS:117-120.
In some embodiments, the ASO is 16, 17, 18, 19, 20, 21, 22, 23, 24,
or 25 nucleotides in length or any range therein. In some
embodiments, the ASO is 20, 21, or 22 nucleotides in length. In
some embodiments, the ASO is 20 nucleotides in length. In certain
embodiments, at least 80% of the unspecified nucleotides in the ASO
are complementary to a wild-type human KRAS gene, e.g., at least
80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%. In
certain embodiments, at least 80% of the unspecified nucleotides in
the ASO are complementary to a mutant human KRAS gene, e.g., at
least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or
99%. In certain embodiments, the ASO is 17-25 nucleotides in length
and comprises an additional nucleotide C at the 5' end of the
sequence of one of SEQ ID NOS:117-120. In certain embodiments, the
ASO is 18-25 nucleotides in length and comprises additional
nucleotides AC at the 5' end of the sequence of one of SEQ ID
NOS:117-120. In certain embodiments, the ASO is 19-25 nucleotides
in length and comprises additional nucleotides CAC at the 5' end of
the sequence of one of SEQ ID NOS:117-120. In certain embodiments,
the ASO is 20-25 nucleotides in length and comprises additional
nucleotides GCAC at the 5' end of the sequence of one of SEQ ID
NOS:117-120.
In some embodiments, the antisense oligonucleotide consists of a
sequence selected from:
a) GCACTCTTGCCTACGCCACA (SEQ ID NO:124) targeted to a human KRAS
mRNA encoding a G12C mutation;
b) GCACTCTTGCCTACGCCATC (SEQ ID NO:125) targeted to a human KRAS
mRNA encoding a G12D mutation;
c) GCACTCTTGCCTACGCCAAC (SEQ ID NO:126) targeted to a human KRAS
mRNA encoding a G13V mutation; or
d) GCACTCTTGCCTACGTCACC (SEQ ID NO:127) targeted to a human KRAS
mRNA encoding a G13D mutation.
The ASO may be comprised of deoxyribonucleotides, ribonucleotides,
or a combination thereof.
In some embodiments, the ASO comprises at least one non-naturally
occurring chemical modification. In certain embodiments, at least
1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, or
19 of the nucleotide linkages are chemically modified. In some
embodiments, the ASO comprises at least one phosphorothioate
linkage. In some embodiments, the ASO comprises 1, 2, 3, 4, 5, 6,
7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, or 19 phosphorothioate
linkages. In some embodiments, the ASO comprises all
phosphorothioate linkages.
In certain embodiments, at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11,
12, 13, 14, 15, 16, 17, 18, or 19 of the nucleotides are chemically
modified. In some embodiments, the ASO comprises at least one
modified nucleotide at or near the 5' end and/or the 3' end, e.g.,
within 5 nucleotides of 5' end and/or the 3' end, e.g., at least 1,
2, 3, 4, or 5 modified nucleotides. In some embodiments, the ASO
comprises at least five modified nucleotides at each of the 5' end
and the 3' end. In some embodiments, at least one of the modified
nucleotides is a 2'-MOE-modified nucleotide. In some embodiments,
all of the modified nucleotides is a 2'-MOE-modified nucleotide. In
some embodiments, the ASO comprises at least 3 2'-MOE-modified
nucleotides at each of the 5' end and/or the 3' end, e.g., at least
4 or at least 5.
In certain embodiments, the ASO consists a sequence selected
from:
TABLE-US-00007 a) (SEQ ID NO: 70)
G*C*A*C*T*C*T*T*G*C*C*T*A*C*G*C*C*A*C*A; b) (SEQ ID NO: 71)
G*C*A*C*T*C*T*T*G*C*C*T*A*C*G*C*C*A*T*C; c) (SEQ ID NO: 72)
G*C*A*C*T*C*T*T*G*C*C*T*A*C*G*C*C*A*A*C; or d) (SEQ ID NO: 73)
G*C*A*C*T*C*T*T*G*C*C*T*A*C*G*T*C*A*C*C;
wherein * indicates a phosphorothioate linkage and bold indicates a
2'-MOE-modified nucleotide. In some embodiments, the ASO comprises,
consists essentially of, or consists of a sequence at least 90%
identical to one of SEQ ID NOS:70-73, e.g., at least 90%, 91%, 92%,
93%, 94%, 95%, 96%, 97%, 98%, or 99% identical.
In some embodiments, at least one modified nucleotide is a locked
nucleic acid nucleotide, e.g., at least 1, 2, 3, 4, or 5 modified
nucleotides. The lock nucleic acid may be, without limitation, a
methylene bridge connecting the 2' oxygen and 4' carbon on the
ribose to lock the ribose in the 3'-endo (North) conformation.
In certain embodiments, the ASO consists of a sequence selected
from:
TABLE-US-00008 a) (SEQ ID NO: 74)
G*C*A*C*T*C*T*T*G*C*C*T*A*C*G*C*C*A*C*+A b) (SEQ ID NO: 75)
G*C*A*C*T*C*T*T*G*C*C*T*A*C*G*C*C*A*+T*C; c) (SEQ ID NO: 76)
G*C*A*C*T*C*T*T*G*C*C*T*A*C*G*C*C*A*+A*C; or d) (SEQ ID NO: 77)
G*C*A*C*T*C*T*T*G*C*C*T*A*C*G*+T*C*A*C*C;
wherein * indicates a phosphorothioate linkage, bold indicates a 2'
methoxymethyl-modified nucleotide, and + indicates the following
nucleotide is a locked nucleic acid. In some embodiments, the ASO
comprises, consists essentially of, or consists of a sequence at
least 90% identical to one of SEQ ID NOS:74-76, e.g., at least 90%,
91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical.
Chemically-Modified siRNAs
One aspect of the invention relates to a siRNA molecule targeted to
a naturally-occurring human KRAS mRNA encoding a mutation selected
from G12C, G12D, G12V, and G13D, wherein the siRNA comprises as
least one chemical modification. In some embodiments, the siRNA
molecule is fully chemically modified. The term "fully
chemically-modified" means that every nucleotide in the siRNA
contains a chemical modification. In some embodiments, each
nucleotide in the siRNA molecule is modified with a 2'-O-methyl
group or a 2'-fluoro group.
In certain embodiments, at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11,
12, 13, 14, 15, 16, 17, 18, or 19 of the nucleotide linkages in the
siRNA are chemically modified. In some embodiments, the siRNA
comprises at least one phosphorothioate linkage. In some
embodiments, the siRNA comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11,
12, 13, 14, 15, 16, 17, 18, or 19 phosphorothioate linkages. In
some embodiments, the siRNA comprises all phosphorothioate
linkages.
In certain embodiments, the siRNA molecule comprising at least one
chemical modification comprises a sense strand and an antisense
strand, wherein the siRNA molecule comprises one of the following
pairs of sequences:
sense strand of SEQ ID NO:128 and antisense strand of SEQ ID
NO:129;
sense strand of SEQ ID NO:130 and antisense strand of SEQ ID
NO:131;
sense strand of SEQ ID NO:132 and antisense strand of SEQ ID
NO:133;
sense strand of SEQ ID NO:134 and antisense strand of SEQ ID
NO:135;
sense strand of SEQ ID NO:136 and antisense strand of SEQ ID
NO:137;
sense strand of SEQ ID NO:138 and antisense strand of SEQ ID
NO:139;
sense strand of SEQ ID NO:140 and antisense strand of SEQ ID
NO:141;
sense strand of SEQ ID NO:142 and antisense strand of SEQ ID
NO:143;
sense strand of SEQ ID NO:144 and antisense strand of SEQ ID
NO:145;
sense strand of SEQ ID NO:146 and antisense strand of SEQ ID
NO:147;
sense strand of SEQ ID NO:148 and antisense strand of SEQ ID
NO:149;
sense strand of SEQ ID NO:150 and antisense strand of SEQ ID
NO:151;
sense strand of SEQ ID NO:152 and antisense strand of SEQ ID
NO:153;
sense strand of SEQ ID NO:154 and antisense strand of SEQ ID
NO:155;
sense strand of SEQ ID NO:156 and antisense strand of SEQ ID
NO:157; or
sense strand of SEQ NO:158 and antisense strand of SEQ ID
NO:159.
In some embodiments, the siRNA comprises, consists essentially of,
or consists of a sequence at least 90% identical to one of SEQ ID
NOS:128-159, e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%,
98%, or 99% identical.
TABLE-US-00009 TABLE 1 Fully modified siRNA sequences Strand
Sequence (5'-3') SEQ ID NO S GAGCUUGUGGCGUAGGCAAGA 128 AS
UUGCCUACGCCACAAGCUCCA 129 S GAGCUGAUGGCGUAGGCAAGA 130 AS
UUGCCUACGCCAUCAGCUCCA 131 S GAGCUGGUGACGUAGGCAAGA 137 AS
UUGCCUACGUCACCAGCUCCA 133 S AGUUGGAGCUUGUGGCGUAGG 134 AS
UACGCCACAAGCUCCAACUAC 135 S AGUUGGAGCUGAUGGCGUAGG 136 AS
UACGCCAUCAGCUCCAACUAC 137 S AGUUGGAGCUGGUGACGUAGG 138 AS
UACGUCACCAGCUCCAACUAC 139 S GGUAGUUGGAGCUGGUGACGU 140 AS
GUCACCAGCUCCAACUACCAC 141 S AGUUGGAGCUGUUGGCGUAGG 142 AS
UACGCCAACAGCUCCAACUAC 143 S GAGCUGUUGGCGUAGGCAAGA 144 AS
UUGCCUACGCCAACAGCUCCA 145 S GAGCUGAUGGCGUAGGCAAGA 146 AS
UUGCCUACGCCAUCAGCUCCA 147 S GAGCUGGUGACGUAGGCAAGA 148 AS
UUGCCUACGUCACCAGCUCCA 149 S AGUUGGAGCUUGUGGCGUAGG 150 AS
UACGCCACAAGCUCCAACUAC 151 S AGUUGGAGCUGAUGGCGUAGG 152 AS
UACGCCAUCAGCUCCAACUAC 153 S AGUUGGAGCUGGUGACGUAGG 154 AS
UACGUCACCAGCUCCAACUAC 155 S AGUUGGAGCUGUUGGCGUAGG 156 AS
UACGCCAACAGCUCCAACUAC 157 S GAGCUGUUGGCGUAGGCAAGA 158 AS
UUGCCUACGCCAACAGCACCA 159 S - sense strand AS - antisense
strand
In certain embodiments, the siRNA molecule is fully chemically
modified and comprises a sense strand and an antisense strand,
wherein the siRNA molecule comprises one of the following pairs of
sequences:
sense strand of SEQ ID NO:78 and antisense strand of SEQ ID
NO:79;
sense strand of SEQ ID NO:80 and antisense strand of SEQ ID
NO:81;
sense strand of SEQ ID NO:82 and antisense strand of SEQ ID
NO:83;
sense strand of SEQ ID NO:84 and antisense strand of SEQ ID
NO:85;
sense strand of SEQ ID NO:86 and antisense strand of SEQ ID
NO:87;
sense strand of SEQ ID NO:88 and antisense strand of SEQ ID
NO:89;
sense strand of SEQ ID NO:90 and antisense strand of SEQ ID
NO:91;
sense strand of SEQ ID NO:92 and antisense strand of SEQ ID
NO:93;
sense strand of SEQ ID NO:94 and antisense strand of SEQ ID
NO:95;
sense strand of SEQ ID NO:96 and antisense strand of SEQ ID
NO:97;
sense strand of SEQ ID NO:98 and antisense strand of SEQ ID
NO:99;
sense strand of SEQ ID NO:100 and antisense strand of SEQ ID
NO:101;
sense strand of SEQ ID NO:102 and antisense strand of SEQ ID
NO:103;
sense strand of SEQ ID NO:104 and antisense strand of SEQ ID
NO:105;
sense strand of SEQ ID NO:106 and antisense strand of SEQ ID
NO:107; or
sense strand of SEQ ID NO:108 and antisense strand of SEQ ID
NO:109.
In some embodiments, the siRNA comprises, consists essentially of,
or consists of a sequence at least 90% identical to one of SEQ ID
NOS:78-109, e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%,
98%, or 99% identical.
Another aspect of the invention relates to an siRNA molecule
targeted to human KRAS mRNA, wherein the sense strand of the siRNA
comprises, consists essentially of, or consists of the sequence of
SEQ ID NO:50 or SEQ NO:51, and wherein the siRNA comprises at least
one non-naturally occurring chemical modification. In some
embodiments, at least 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 of the
nucleotides in the siRNA are chemically modified. In some
embodiments, the siRNA is fully chemically-modified. In some
embodiments, each nucleotide in the siRNA molecule is modified with
a 2'-O-methyl group or a 2'-fluoro group.
In certain embodiments, at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11,
12, 13, 14, 15, 16, 17, 18, or 19 of the nucleotide linkages in the
siRNA are chemically modified. In some embodiments, the siRNA
comprises at least one phosphorothioate linkage. In some
embodiments, the siRNA comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11,
12, 13, 14, 15, 16, 17, 18, or 19 phosphorothioate linkages. In
some embodiments, the siRNA comprises all phosphorothioate
linkages.
In certain embodiments, the fully chemically-modified siRNA
molecule comprises a sense strand and an antisense strand, wherein
the siRNA molecule comprises one of the following pairs of
sequences:
sense strand of SEQ ID NO:110 and antisense strand of SEQ ID
NO:111; or
sense strand of SEQ ID NO:112 and antisense strand of SEQ ID
NO:113.
In some embodiments, the siRNA comprises, consists essentially of,
or consists of a sequence at least 90% identical to one of SEQ ID
NOS:110-113, e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%,
98%, or 99% identical.
The double stranded RNA molecule, ASO, or chemically-modified siRNA
molecule may be constructed using chemical synthesis and enzymatic
ligation reactions by procedures known in the art. For example, a
double stranded RNA, ASO, or chemically-modified siRNA molecule may
be chemically synthesized using naturally occurring nucleotides or
various modified nucleotides designed to increase the biological
stability of the molecules or to increase the physical stability of
the duplex formed between the double stranded RNA, ASO, or
chemically-modified siRNA molecule and target nucleotide sequences,
e.g., phosphorothioate derivatives and acridine substituted
nucleotides can be used. Examples of modified nucleotides which can
be used to generate the double stranded RNA, ASO, or
chemically-modified siRNA molecule include, but are not limited to,
5-fluorouracil, 5-bromouracil, 5-chlorouracil, 5-iodouracil,
hypoxanthine, xanthine, 4-acetylcytosine, 5-(carboxyhydroxylmethyl)
uracil, 5-carboxymethylaminomethyl-2-thiouridine,
5-carboxymethylaminomet-hyluracil, dihydrouracil,
beta-D-galactosylqueosine, inosine, N6-isopentenyladenine,
1-methylguanine, 1-methylinosine, 2,2-dimethylguanine,
2-methyladenine, 2-methylguanine, 3-methylcytosine,
5-methylcytosine, N6-adenine, 7-methylguanine,
5-methylaminomethyluracil, 5-methoxyaminomethyl-2-thiouracil,
beta-D-mannosylqueosine, 5'-methoxycarboxymethyluracil,
5-methoxyuracil, 2-methylthio-N6-isopentenyladenine,
uracil-5-oxyacetic acid (v), wybutoxosine, pseudouracil, queosine,
2-thiocytosine, 5-methyl-2-thiouracil, 2-thiouracil, 4-thiouracil,
5-methyluracil, uracil-5-oxyacetic acid methylester,
uracil-5-oxyacetic acid (v), 5-methyl-2-thiouracil,
3-(3-amino-3-N-2-carboxypropyl) uracil, (acp3)w, and
2,6-diaminopurine. Alternatively, the double stranded RNA or ASO
can be produced using an expression vector into which a nucleic
acid encoding the double stranded RNA or ASO has been cloned.
The double stranded RNA, ASO, or chemically-modified siRNA molecule
can further include nucleotide sequences wherein at least one, or
all, of the internucleotide bridging phosphate residues are
modified phosphates, such as methyl phosphonates, methyl
phosphonothioates, phosphoromorpholidates, phosphoropiperazidates
and phosphoramidates. For example, every one or every other one of
the internucleotide bridging phosphate residues can be modified as
described. In another non-limiting example, the double stranded
RNA, ASO, or chemically-modified siRNA molecule is a nucleotide
sequence in which at least one, or all, of the nucleotides contain
a 2' lower alkyl moiety (e.g., C.sub.1-C.sub.4, linear or branched,
saturated or unsaturated alkyl, such as methyl, ethyl, ethenyl,
propyl, 1-propenyl, 2-propenyl, and isopropyl). In another example,
one or more of the nucleotides may be a 2'-fluoro nucleotide, a
2-O-methyl nucleotide, or a locked nucleic acid nucleotide. For
example, every one or every other one of the nucleotides can be
modified as described. See also, Furdon et al., Nucleic Acids Res.
17:9193 (1989); Agrawal et al., Proc. Natl. Acad. Sci. USA 87:1401
(1990); Baker et al., Nucleic Acids Res. 18:3537 (1990); Sproat et
al., Nucleic Acids Res. 17:3373 (1989); Walder and Walder, Proc.
Natl. Acad. Sci. USA 85:5011 (1988); incorporated by reference
herein in their entireties for their teaching of methods of making
polynucleotide molecules, including those containing modified
nucleotide bases).
The invention further relates to a nucleic acid construct
comprising the RNA molecule or ASO of the invention. The invention
further relates to a nucleic acid construct encoding the RNA
molecule or ASO of the invention and a nucleic acid construct
comprising the nucleic acid molecule encoding the RNA molecule or
ASO. In each of these embodiments, the nucleic acid construct may
be a vector or a plasmid, e.g., an expression vector.
Another aspect of the invention relates to a composition comprising
the RNA molecule. ASO, chemically-modified siRNA molecule, or
nucleic acid construct of the invention and another component,
e.g., a suitable carrier. In some embodiments, the composition
comprises two or more of the RNA molecules, ASOs,
chemically-modified siRNA molecules, or nucleic acid constructs of
the invention, wherein the two or more RNA molecules. ASO, or
chemically-modified siRNA molecule each comprise a different
antisense strand. In certain embodiments, the two or more RNA
molecules are present on the same nucleic acid construct, on
different nucleic acid constructs or any combination thereof. In
some embodiments, the composition is a pharmaceutical composition
comprising the RNA molecule(s), ASO(s), chemically-modified siRNA
molecule(s), or nucleic acid construct(s) of the invention and a
pharmaceutically acceptable carrier.
It is understood that the compositions of this invention can
comprise, consist essentially of, or consist of any of the RNA
molecules, ASOs, chemically-modified siRNA molecules, and nucleic
acid constructs in any combination and in any ratio relative to one
another. Furthermore, by "two or more" is meant 2, 3, 4, 5, 6, 7,
8, 9, 10, etc., up to a total number of RNA molecules, ASOs,
chemically-modified siRNA molecules, and nucleic acid constructs of
this invention. In some embodiments, the compositions comprise,
consist essentially of or consist of the RNA molecules of SEQ ID
NO:1 and SEQ ID NO:3.
In some aspects of the invention, the composition or pharmaceutical
composition further comprises additional components that enhance
the delivery of the RNA molecule(s), ASO(s), chemically-modified
siRNA molecule(s), or nucleic acid construct(s) of the invention to
a subject, e.g., by enhancing the stability of the IRNA
molecule(s), ASO(s), chemically-modified siRNA molecule(s), or
nucleic acid construct(s). In some embodiments, the additional
component may be a particle, e.g., a microparticle or nanoparticle.
In some embodiments, the particle is a lipid particle, e.g., a
liposome, e.g., a microliposome or a nanoliposome. The liposome,
microliposome, or nanoliposome may contain any components known in
the art to be suitable for preparing liposomes. In some
embodiments, the liposome comprises
1,2-dioleoyl-sn-glycero-3-phosphatidylcholine (DOPC). Liposomes may
be prepared by methods known in the art, e.g., as described in
Pecot et al., Mol. Cancer Ther. 13:2876 (2014), incorporated by
reference herein in its entirety. In some embodiments, the RNA
molecule is formed into a stable nucleic acid lipid particle
(SNALP), e.g., using particles such as those provided by Arbutus
Biopharma (Doylestown, Pa.). In certain embodiments, the lipid
particle comprises, consists essentially of, or consists of
cholesterol, 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC),
PEG-cDMA or PEG-cDSA, and
1,2-dilinoleyloxy-3-(N,N-dimethyl)aminopropane (DLinDMA) (see Judge
et al., J. Clin. Invest. 119:661 (2009)). In some embodiments, the
lipid particle comprises two or more of the RNA molecules, ASOs, or
chemically-modified siRNA molecules of the invention, e.g., the RNA
molecules of SEQ ID NO:1 and SEQ ID NO:3. In some embodiments, the
additional component is a targeted delivery moiety to which the RNA
molecule(s), ASO(s), chemically-modified siRNA molecule(s), or
nucleic acid construct(s) or covalently or noncovalently
conjugated, e.g., ligands, aptamers, or monoclonal antibodies.
The present invention encompasses cells comprising the RNA
molecules and/or nucleic acid constructs of the invention. Thus, in
some embodiments, the present invention provides a transformed cell
comprising a RNA molecule and/or a nucleic acid construct and/or a
composition of this invention, wherein the transformed cell has
reduced expression of mutant KRAS as compared to a control
cell.
Methods
Various methods are provided herein, employing the nucleic acid
molecules, nucleic acid constructs, and/or compositions of this
invention. Thus, in one aspect, the present invention provides a
method of inhibiting expression of a mutant human KRAS gene
comprising one or more of the missense mutations G12C, G12D, G12V,
and G13D in a cell, the method comprising contacting the cell with
the RNA molecule, ASO, chemically-modified siRNA molecule, nucleic
acid construct, composition, and/or pharmaceutical composition of
the invention, thereby inhibiting expression of the mutant human
KRAS gene in the cell.
Also provided herein is a method of treating cancer in a subject in
need thereof, wherein the cancer comprises a mutant human KRAS gene
comprising one or more of the missense mutations G12C, G12D, G12V,
and G13D, the method comprising delivering to the subject the RNA
molecule, ASO, chemically-modified siRNA molecule, nucleic acid
construct, composition, and/or pharmaceutical composition of the
invention, thereby treating cancer in the subject. A cancer
comprising a mutant human KRAS gene comprising one or more of the
missense mutations G12C, G12D, G12V, and G13D is a cancer, e.g., a
tumor in which one or more cells express the mutant KRAS gene.
In one embodiment of each of these aspects, the subject may be one
that has been diagnosed with cancer. In another embodiment, the
subject may be one that is at risk of developing cancer (e.g.,
predisposed due to hereditary factors, smoking, viral infection,
exposure to chemicals, etc.). In a further embodiment, the subject
may be one that has been identified as carrying a mutant KRAS gene
and has or has not been diagnosed with cancer.
The double stranded RNA, ASO, or chemically-modified siRNA molecule
of the invention can be delivered directly into a cell by any
method known in the art, e.g., by transfection or microinjection,
e.g., as part of a composition comprising lipid particles. In other
embodiments, the double stranded RNA or ASO can be delivered to a
subject in the form of polynucleotides encoding the RNA or ASO to
produce expression of the double stranded RNA or ASO within the
cells of the subject. Those skilled in the art will appreciate that
the isolated polynucleotides encoding the RNAs or ASOs of the
invention will typically be associated with appropriate expression
control sequences, e.g., transcription/translation control signals
and polyadenylation signals.
It will further be appreciated that a variety of promoter/enhancer
elements can be used depending on the level and tissue-specific
expression desired. The promoter can be constitutive or inducible,
depending on the pattern of expression desired. The promoter can be
native or foreign and can be a natural or a synthetic sequence. By
foreign, it is intended that the transcriptional initiation region
is not found in the wild-type host into which the transcriptional
initiation region is introduced. The promoter is chosen so that it
will function in the target cell(s) of interest.
To illustrate, the RNA or ASO coding sequence can be operatively
associated with a cytomegalovirus (CMV) major immediate-early
promoter, an albumin promoter, an Elongation Factor 1-.alpha.
(EF1-.alpha.) promoter, a P.gamma.K promoter, a MFG promoter, or a
Rous sarcoma virus promoter.
Inducible promoter/enhancer elements include hormone-inducible and
metal-inducible elements, and other promoters regulated by
exogenously supplied compounds, including without limitation, the
zinc-inducible metallothionein (MT) promoter; the dexamethasone
(Dex)-inducible mouse mammary tumor virus (MMTV) promoter; the T7
polymerase promoter system (see WO 98/10088); the ecdysone insect
promoter (No et al., Proc. Natl. Acad. Sci. USA 93:3346 (1996));
the tetracycline-repressible system (Gossen et al., Proc. Natl.
Acad. Sci. USA 89:5547 (1992)); the tetracycline-inducible system
(Gossen et al., Science 268:1766 (1995); see also Harvey et al.,
Curr. Opin. Chem. Biol. 2:512 (1998)); the RU486-inducible system
(Wang et al., Nat. Biotech. 15:239 (1997); Wang et al., Gene Ther.,
4:432 (1997)); and the rapamycin-inducible system (Magari et al.,
J. Clin. Invest. 100:2865 (1997)).
Other tissue-specific promoters or regulatory promoters include,
but are not limited to, promoters that typically confer
tissue-specificity in neurons. These include, but are not limited
to, promoters for synapsin 1, tubulin .alpha.1, platelet-derived
growth factor B-chain, tyrosine hydroxylase, neuron-specific
enolase, and neurofilaments. Skeletal muscle cell promoters
include, but are not limited to, promoters for .beta.-actin, Pitx3,
creatine kinase, and myosin light chain. Cardiac muscle cell
promoters include, but are not limited to, promoters for cardiac
actin, cardiac troponin T, troponin C, myosin light chain-2, and
.alpha.-myosin heavy chain. Islet (beta) cell promoters include,
but are not limited to, glucokinase, gastrin, insulin, and islet
amyloid polypeptide.
Moreover, specific initiation signals are generally required for
efficient translation of inserted RNA or ASO coding sequences.
These translational control sequences, which can include the ATG
initiation codon and adjacent sequences, can be of a variety of
origins, both natural and synthetic.
The isolated nucleic acid encoding the double stranded RNA or ASO
can be incorporated into an expression vector. Expression vectors
compatible with various host cells are well known in the art and
contain suitable elements for transcription and translation of
nucleic acids. Typically, an expression vector contains an
"expression cassette," which includes, in the 5' to 3' direction, a
promoter, a coding sequence encoding a double stranded RNA
operatively associated with the promoter, and, optionally, a
termination sequence including a stop signal for RNA polymerase and
a polyadenylation signal for polyadenylase.
Non-limiting examples of animal and mammalian promoters known in
the art include, but are not limited to, the SV40 early (SV40e)
promoter region, the promoter contained in the 3' long terminal
repeat (LTR) of Rous sarcoma virus (RSV), the promoters of the E1A
or major late promoter (MLP) genes of adenoviruses (Ad), the
cytomegalovirus (CMV) early promoter, the herpes simplex virus
(HSV) thymidine kinase (TK) promoter, baculovirus 1E1 promoter,
elongation factor 1 alpha (EF1) promoter, phosphoglycerate kinase
(PGK) promoter, ubiquitin (Ubc) promoter, an albumin promoter, the
regulatory sequences of the mouse metallothionein-L promoter and
transcriptional control regions, the ubiquitous promoters (HPRT,
vimentin, .alpha.-actin, tubulin and the like), the promoters of
the intermediate filaments (desmin, neurofilaments, keratin, GFAP,
and the like), the promoters of therapeutic genes (of the MDR, CFTR
or factor VIII type, and the like), and pathogenesis and/or
disease-related promoters. In addition, any of these expression
sequences of this invention can be modified by addition of enhancer
and/or regulatory sequences and the like.
Enhancers that may be used in embodiments of the invention include
but are not limited to: an SV40 enhancer, a cytomegalovirus (CMV)
enhancer, an elongation factor I (EF1) enhancer, yeast enhancers,
viral gene enhancers, and the like.
Termination control regions, i.e., terminator or polyadenylation
sequences, may be derived from various genes native to the
preferred hosts. In some embodiments of the invention, the
termination control region may comprise or be derived from a
synthetic sequence, a synthetic polyadenylation signal, an SV40
late polyadenylation signal, an SV40 polyadenylation signal, a
bovine growth hormone (BGH) polyadenylation signal, viral
terminator sequences, or the like.
It will be apparent to those skilled in the art that any suitable
vector can be used to deliver the polynucleotide to a cell or
subject. The vector can be delivered to cells in vivo. In other
embodiments, the vector can be delivered to cells ex vivo, and then
cells containing the vector are delivered to the subject. The
choice of delivery vector can be made based on a number of factors
known in the art, including age and species of the target host, in
vitro versus in vivo delivery, level and persistence of expression
desired, intended purpose (e.g., for therapy or screening), the
target cell or organ, route of delivery, size of the isolated
polynucleotide, safety concerns, and the like.
Suitable vectors include, but are not limited to, plasmid vectors,
viral vectors (e.g., retrovirus, alphavirus; vaccinia virus;
adenovirus, adeno-associated virus and other parvoviruses,
lentivirus, poxvirus, or herpes simplex virus), lipid vectors,
poly-lysine vectors, synthetic polyamino polymer vectors, and the
like.
Any viral vector that is known in the art can be used in the
present invention. Protocols for producing recombinant viral
vectors and for using viral vectors for nucleic acid delivery can
be found in Ausubel et al., Current Protocols in Molecular Biology
(Green Publishing Associates, Inc. and John Wiley & Sons, Inc.,
New York) and other standard laboratory manuals (e.g., Vectors for
Gene Therapy. In: Current Protocols in Human Genetics. John Wiley
and Sons, Inc.: 1997).
Non-viral transfer methods can also be employed. Many non-viral
methods of nucleic acid transfer rely on normal mechanisms used by
mammalian cells for the uptake and intracellular transport of
macromolecules. In particular embodiments, non-viral nucleic acid
delivery systems rely on endocytic pathways for the uptake of the
nucleic acid molecule by the targeted cell. Exemplary nucleic acid
delivery systems of this type include liposomal derived systems,
poly-lysine conjugates, and artificial viral envelopes.
In particular embodiments, plasmid vectors are used in the practice
of the present invention. For example, naked plasmids can be
introduced into muscle cells by injection into the tissue.
Expression can extend over many months, although the number of
positive cells is typically low (Wolff et al., Science 247:247
(1989)). Cationic lipids have been demonstrated to aid in
introduction of nucleic acids into some cells in culture (Feigner
and Ringold, Nature 337:387 (1989)). Injection of cationic lipid
plasmid DNA complexes into the circulation of mice has been shown
to result in expression of the DNA in lung (Brigham et al., Am. J.
Med. Sci. 298:278 (1989)). One advantage of plasmid DNA is that it
can be introduced into non-replicating cells.
In a representative embodiment, a nucleic acid molecule (e.g., a
plasmid) can be entrapped in a lipid particle bearing positive
charges on its surface and, optionally, tagged with antibodies
against cell surface antigens of the target tissue (Mizuno et al.,
No Shinkei Geka 20:547 (1992); PCT publication WO 91/06309;
Japanese patent application 1047381; and European patent
publication EP-A-43075).
Liposomes that consist of amphiphilic cationic molecules are useful
as non-viral vectors for nucleic acid delivery in vitro and in vivo
(reviewed in Crystal, Science 270:404 (1995); Blaese et al., Cancer
Gene Ther. 2:291 (1995); Behr et al., Bioconjugate Chem. 5:382
(1994); Remy et al., Bioconjugate Chem. 5:647 (1994); and Gao et
al., Gene Therapy 2:710 (1995)). The positively charged liposomes
are believed to complex with negatively charged nucleic acids via
electrostatic interactions to form lipid:nucleic acid complexes.
The lipid:nucleic acid complexes have several advantages as nucleic
acid transfer vectors. Unlike viral vectors, the lipid:nucleic acid
complexes can be used to transfer expression cassettes of
essentially unlimited size. Since the complexes lack proteins, they
can evoke fewer immunogenic and inflammatory responses. Moreover,
they cannot replicate or recombine to form an infectious agent and
have low integration frequency. A number of publications have
demonstrated that amphiphilic cationic lipids can mediate nucleic
acid delivery in vivo and in vitro (Felgner et al., Proc. Natl.
Acad Sci. USA 84:7413 (1987); Loeffler et al., Meth. Enzymol.
217:599 (1993); Felgner et al., J. Biol. Chem. 269:2550
(1994)).
Several groups have reported the use of amphiphilic cationic
lipid:nucleic acid complexes for in vivo transfection both in
animals and in humans (reviewed in Gao et al., Gene Therapy 2:710
(1995); Zhu et al., Science 261:209 (1993); and Thierry et al.,
Proc. Natl. Acad. Sci. USA 92:9742 (1995)). U.S. Pat. No. 6,410,049
describes a method of preparing cationic lipid:nucleic acid
complexes that have a prolonged shelf life.
Nuclear localization signals can also be used to enhance the
targeting of the double stranded RNA or expression vector into the
proximity of the nucleus and/or its entry into the nucleus. Such
nuclear localization signals can be a protein or a peptide such as
the SV40 large Tag NLS or the nucleoplasmin NLS. These nuclear
localization signals interact with a variety of nuclear transport
factors such as the NLS receptor (karyopherin alpha) which then
interacts with karyopherin beta.
Expression vectors can be designed for expression of stranded RNA
or ASOs in prokaryotic or eukaryotic cells. For example, stranded
RNA or ASOs can be expressed in bacterial cells such as E. coli,
insect cells (e.g., the baculavirus expression system), yeast
cells, plant cells or mammalian cells. Some suitable host cells are
discussed further in Goeddel, Gene Expression Technology: Methods
in Enzymology 185, Academic Press, San Diego, Calif. (1990).
Examples of bacterial vectors include, but are not limited to,
pQE70, pQE60, pQE-9 (Qiagen), pBS, pD10, phagescript, psiX174,
pbluescript SK, pbsks, pNH8A, pNH16a, pNH18A, pNH46A (Stratagene);
ptrc99a, pKK223-3, pKK233-3, pDR540, and pRIT5 (Pharmacia).
Examples of vectors for expression in the yeast S. cerevisiae
include pYepSecl (Baldari et al., EMBO J. 6:229 (1987)), pMFa
(Kurjan and Herskowitz, Cell 30:933 (1982)), pJRY88 (Schultz et
al., Gene 54:113 (1987)), and pYES2 (Invitrogen Corporation, San
Diego, Calif.). Non-limiting examples of baculovirus vectors
available for expression of nucleic acids to produce proteins in
cultured insect cells (e.g., Sf 9 cells) include the pAc series
(Smith et al., Mol. Cell. Biol. 3:2156 (1983)) and the pVL series
(Lucklow and Summers Virology 170:31 (1989)).
Examples of mammalian expression vectors include pWLNEO, pSV2CAT,
pOG44, pXT1, pSG (Stratagene) pSVK3, PBPV, pMSG, PSVL (Pharmacia),
pCDM8 (Seed, Nature 329:840 (1987)) and pMT2PC (Kaufman et al.,
EMBO J. 6:187 (1987)). When used in mammalian cells, the expression
vector's control functions are often provided by viral regulatory
elements. For example, commonly used promoters are derived from
polyoma, adenovirus 2, cytomegalovirus and Simian Virus 40.
Viral vectors have been used in a wide variety of gene delivery
applications in cells, as well as living animal subjects. Viral
vectors that can be used include, but are not limited to,
retrovirus, lentivirus, adeno-associated virus, poxvirus,
alphavirus, baculovirus, vaccinia virus, herpes virus, Epstein-Barr
virus, adenovirus, geminivirus, and caulimovirus vectors.
Non-limiting examples of non-viral vectors include plasmids,
liposomes, electrically charged lipids (cytofectins), nucleic
acid-protein complexes, and biopolymers. In addition to a nucleic
acid of interest, a vector may also comprise one or more regulatory
regions, and/or selectable markers useful in selecting, measuring,
and monitoring nucleic acid transfer results (delivery to specific
tissues, duration of expression, etc.).
In addition to the regulatory control sequences discussed above,
the recombinant expression vector can contain additional nucleotide
sequences. For example, the recombinant expression vector can
encode a selectable marker gene to identify host cells that have
incorporated the vector.
Vector DNA can be introduced into prokaryotic or eukaryotic cells
via conventional transformation or transfection techniques. As used
herein, the terms "transformation" and "transfection" refer to a
variety of art-recognized techniques for introducing foreign
nucleic acids (e.g., DNA and RNA) into a host cell, including, but
are not limited to, calcium phosphate or calcium chloride
co-precipitation, DEAE-dextran-mediated transfection, lipofection,
electroporation, microinjection, DNA-loaded liposomes,
lipofectamine-DNA complexes, cell sonication, gene bombardment
using high velocity microprojectiles, and viral-mediated
transfection. Suitable methods for transforming or transfecting
host cells can be found in Sambrook et al., Molecular Cloning: A
Laboratory Manual 2nd Ed. (Cold Spring Harbor, N.Y., 1989), and
other laboratory manuals.
If stable integration is desired, often only a small fraction of
cells (in particular, mammalian cells) integrate the foreign DNA
into their genome. In order to identify and select integrants, a
nucleic acid that encodes a selectable marker (e.g., resistance to
antibiotics) can be introduced into the host cells along with the
nucleic acid of interest. Preferred selectable markers include
those that confer resistance to drugs, such as G418, hygromycin and
methotrexate. Nucleic acids encoding a selectable marker can be
introduced into a host cell on the same vector as that comprising
the nucleic acid of interest or can be introduced on a separate
vector. Cells stably transfected with the introduced nucleic acid
can be identified by drug selection (e.g., cells that have
incorporated the selectable marker gene will survive, while the
other cells die).
In one embodiment, the double stranded RNA, ASO, or
chemically-modified siRNA molecule of the invention is administered
directly to the subject. Generally, the compounds of the invention
will be suspended in a pharmaceutically-acceptable carrier (e.g.,
physiological saline) and administered orally, topically, or by
intravenous infusion, or injected subcutaneously, intramuscularly,
intracranially, intrathecally, intraperitoneally, intrarectally,
intravaginally, intranasally, intragastrically, intratracheally, or
intrapulmonarily. They are preferably delivered directly to the
site of the disease or disorder, such as the lung, intestine, or
pancreas. The dosage required depends on the choice of the route of
administration; the nature of the formulation; the nature of the
patient's illness; the subject's size, weight, surface area, age,
and sex; other drugs being administered; and the judgment of the
attending physician. Suitable dosages are in the range of
0.01-100.0 .mu.g/kg. Wide variations in the needed dosage are to be
expected in view of the differing efficiencies of various routes of
administration. For example, oral administration would be expected
to require higher dosages than administration by i.v. injection
(e.g., 2-, 3-, 4-, 6-, 8-, 10-; 20-, 50-, 100-, 150-, or more
fold). Variations in these dosage levels can be adjusted using
standard empirical routines for optimization as is well understood
in the art. Administrations can be single or multiple.
Encapsulation of the inhibitor in a suitable delivery vehicle e.g.,
polymeric microparticles or implantable devices) may increase the
efficiency of delivery, particularly for oral delivery.
According to certain embodiments, the double stranded RNA, ASO, or
chemically-modified siRNA molecule can be targeted to specific
cells or tissues in vivo. Targeting delivery vehicles, including
liposomes and viral vector systems are known in the art. For
example, a liposome can be directed to a particular target cell or
tissue by using a targeting agent, such as an antibody, soluble
receptor or ligand, incorporated with the liposome, to target a
particular cell or tissue to which the targeting molecule can bind.
Targeting liposomes are described, for example, in Ho et al.,
Biochemistry 25:5500 (1986); Ho et al., J. Biol. Chem. 262:13979
(1987); Ho et al., J. Biol. Chem. 262:13973 (1987); and U.S. Pat.
No. 4,957,735 to Huang et al., each of which is incorporated herein
by reference in its entirety). Enveloped viral vectors can be
modified to deliver a nucleic acid molecule to a target cell by
modifying or substituting an envelope protein such that the virus
infects a specific cell type. In adenoviral vectors, the gene
encoding the attachment fibers can be modified to encode a protein
domain that binds to a cell-specific receptor. Herpesvirus vectors
naturally target the cells of the central and peripheral nervous
system. Alternatively, the route of administration can be used to
target a specific cell or tissue. For example, intracoronary
administration of an adenoviral vector has been shown to be
effective for the delivery of a gene to cardiac myocytes (Maurice
et al., J. Clin. Invest. 104:21 (1999)). Intravenous delivery of
cholesterol-containing cationic liposomes has been shown to
preferentially target pulmonary tissues (Liu et al., Nature
Biotechnol. 15:167 (1997)), and effectively mediate transfer and
expression of genes in vivo. Other examples of successful targeted
in vivo delivery of nucleic acid molecules are known in the art.
Finally, a recombinant nucleic acid molecule can be selectively
(i.e., preferentially, substantially exclusively) expressed in a
target cell by selecting a transcription control sequence, and
preferably, a promoter, which is selectively induced in the target
cell and remains substantially inactive in non-target cells.
The double stranded RNA, ASO, or chemically-modified siRNA molecule
of the present invention can optionally be delivered in conjunction
with other therapeutic agents. The additional therapeutic agents
can be delivered concurrently with the double stranded RNA, ASO, or
chemically-modified siRNA molecule of the invention. As used
herein, the word "concurrently" means sufficiently close in time to
produce a combined effect (that is, concurrently can be
simultaneously, or it can be two or more events occurring within a
short time period before or after each other). In one embodiment,
the double stranded RNA, ASO, or chemically-modified siRNA molecule
of the invention are administered in conjunction with agents useful
for treating cancer, such as: 1) vinca alkaloids (e.g.,
vinblastine, vincristine); 2) epipodophyllotoxins (e.g., etoposide
and teniposide); 3) antibiotics (e.g., dactinomycin (actinomycin
D), daunorubicin (daunomycin; rubidomycin), doxorubicin, bleomycin,
plicamycin (mithramycin), and mitomycin (mitomycin C)); 4) enzymes
(e.g., L-asparaginase); 5) biological response modifiers (e.g.,
interferon-alfa); 6) platinum coordinating complexes (e.g.,
cisplatin and carboplatin); 7) atithracenediones (e.g.,
mitoxantrone); 8) substituted ureas hydroxyurea); 9)
methylhydrazine derivatives (e.g., procarbazine (N-methylhydrazine;
MIH)); 10) adrenocortical suppressants (e.g., mitotane (o,p'-DDD)
and aminoglutethimide); 11) adrenocorticosteroids (e.g.,
prednisone); 12) progestins (e.g., hydroxyprogesterone caproate,
medroxyprogesterone acetate, and megestrol acetate); 13) estrogens
(e.g., diethylstilbestrol and ethinyl estradiol); 14) antiestrogens
(e.g., tamoxifen); 15) androgens (e.g., testosterone propionate and
fluoxymesterone); 16) antiandrogens (e.g., flutamide): and 17)
gonadotropin-releasing hormone analogs (e.g., leuprolide). In
another embodiment, the compounds of the invention are administered
in conjunction with anti-angiogenesis agents, such as antibodies to
VEGF (e.g., bevacizumab (AVASTIN), ranibizumab (LUCENTIS)) and
other promoters of angiogenesis (e.g., bFGF, angiopoietin-1),
antibodies to alpha-v/beta-3 vascular integrin (e.g., VITAXIN),
angiostatin, endostatin, dalteparin, ABT-510, CNGRC peptide TNF
alpha conjugate, cyclophosphamide, combretastatin A4 phosphate,
dimethylxanthenone acetic acid, docetaxel, lenalidomide,
enzastaurin, paclitaxel, paclitaxel albumin-stabilized nanoparticle
formulation (Abraxane), soy isoflavone (Genistein), tamoxifen
citrate, thalidomide, ADH-1 (EXHERIN), AG-013736, AMG-706, AZD2171,
sorafenib tosylate, BMS-582664, CHIR-265, pazopanib, PI-88,
vatalanib, everolimus, suramin, sunitinib malate, XL184, ZD6474,
ATN-161, cilenigtide, and celecoxib, or any combination
thereof.
The term "cancer," as used herein, refers to any benign or
malignant abnormal growth of cells. Examples include, without
limitation, breast cancer, prostate cancer, lymphoma, skin cancer,
pancreatic cancer, colon cancer, melanoma, malignant melanoma,
ovarian cancer, brain cancer, primary brain carcinoma, head-neck
cancer, glioma, glioblastoma, liver cancer, bladder cancer,
non-small cell lung cancer, head or neck carcinoma, breast
carcinoma, ovarian carcinoma, lung carcinoma, small-cell lung
carcinoma, Wilms' tumor, cervical carcinoma, testicular carcinoma,
bladder carcinoma, pancreatic carcinoma, stomach carcinoma, colon
carcinoma, prostatic carcinoma, genitourinary carcinoma, thyroid
carcinoma, esophageal carcinoma, myeloma, multiple myeloma, adrenal
carcinoma, renal cell carcinoma, endometrial carcinoma, adrenal
cortex carcinoma, malignant pancreatic insulinoma, malignant
carcinoid carcinoma, choriocarcinoma, mycosis timgoides, malignant
hypercalcemia, cervical hyperplasia, leukemia, acute lymphocytic
leukemia, chronic lymphocytic leukemia, acute myelogenous leukemia,
chronic myelogenous leukemia, chronic granulocytic leukemia, acute
granulocytic leukemia, hairy cell leukemia, neuroblastoma,
rhabdomyosarcoma, Kaposi's sarcoma, polycythemia vera, essential
thrombocytosis, Hodgkin's disease, non-Hodgkin's lymphoma,
soft-tissue sarcoma, osteogenic sarcoma, primary macroglobulinemia,
and retinoblastoma. In some embodiments, the cancer is selected
from the group of tumor-forming cancers.
Pharmaceutical Compositions
As a further aspect, the invention provides pharmaceutical
formulations and methods of administering the same to achieve any
of the therapeutic effects (e.g., treatment of cancer) discussed
above. The pharmaceutical formulation may comprise any of the
reagents discussed above in a pharmaceutically acceptable
carrier.
By "pharmaceutically acceptable" it is meant a material that is not
biologically or otherwise undesirable, i.e., the material can be
administered to a subject without causing any undesirable
biological effects such as toxicity.
The formulations of the invention can optionally comprise medicinal
agents, pharmaceutical agents, carriers, adjuvants, dispersing
agents, diluents, and the like.
The double stranded RNA, ASO, chemically-modified siRNA molecule,
or nucleic acid construct of the invention can be formulated for
administration in a pharmaceutical carrier in accordance with known
techniques. See, e.g., Remington, The Science And Practice of
Pharmacy (9.sup.th Ed. 1995). In the manufacture of a
pharmaceutical formulation according to the invention, the double
stranded RNA, ASO, or chemically-modified siRNA molecule (including
the physiologically acceptable salts thereof) is typically admixed
with, inter alia, an acceptable carrier. The carrier can be a solid
or a liquid, or both, and is preferably formulated with the double
stranded RNA, ASO, or chemically-modified siRNA molecule as a
unit-dose formulation, for example, a tablet, which can contain
from 0.01 or 0.5% to 95% or 99% by weight of the double stranded
RNA, ASO, or chemically-modified siRNA molecule. One or more double
stranded RNAs, ASOs, or chemically-modified siRNA molecules can be
incorporated in the formulations of the invention, which can be
prepared by any of the well-known techniques of pharmacy.
A further aspect of the invention is a method of treating subjects
in vivo, comprising administering to a subject a pharmaceutical
composition comprising a double stranded RNA, ASO, or
chemically-modified siRNA molecule of the invention in a
pharmaceutically acceptable carrier, wherein the pharmaceutical
composition is administered in a therapeutically effective amount.
Administration of the double stranded RNA, ASO, or
chemically-modified siRNA molecule of the present invention to a
human subject or an animal in need thereof can be by any means
known in the art for administering compounds.
Non-limiting examples of formulations of the invention include
those suitable for oral, rectal, buccal (e.g., sub-lingual),
vaginal, parenteral (e.g., subcutaneous, intramuscular including
skeletal muscle, cardiac muscle, diaphragm muscle and smooth
muscle, intradermal, intravenous, intraperitoneal), topical (i.e.,
both skin and mucosal surfaces, including airway surfaces),
intranasal, transdermal, intraarticular, intracranial, intrathecal,
and inhalation administration, administration to the liver by
intraportal delivery, as well as direct organ injection (e.g., into
the liver, into a limb, into the brain or spinal cord for delivery
to the central nervous system, into the pancreas, or into a tumor
or the tissue surrounding a tumor). The most suitable route in any
given case will depend on the nature and severity of the condition
being treated and on the nature of the particular compound which is
being used. In some embodiments, it may be desirable to deliver the
formulation locally to avoid any side effects associated with
systemic administration. For example, local administration can be
accomplished by direct injection at the desired treatment site, by
introduction intravenously at a site near a desired treatment site
(e.g., into a vessel that feeds a treatment site). In some
embodiments, the formulation can be delivered locally to ischemic
tissue. In certain embodiments, the formulation can be a slow
release formulation, e.g., in the form of a slow release depot.
For injection, the carrier will typically be a liquid, such as
sterile pyrogen-free water, pyrogen-free phosphate-buffered saline
solution, bacteriostatic water, or Cremophor EL[R] (BASF,
Parsippany, N.J.). For other methods of administration, the carrier
can be either solid or liquid.
For oral administration, the compound can be administered in solid
dosage forms, such as capsules, tablets, and powders, or in liquid
dosage forms, such as elixirs, syrups, and suspensions. Compounds
can be encapsulated in gelatin capsules together with inactive
ingredients and powdered carriers, such as glucose, lactose,
sucrose, mannitol, starch, cellulose or cellulose derivatives,
magnesium stearate, stearic acid, sodium saccharin, talcum,
magnesium carbonate and the like. Examples of additional inactive
ingredients that can be added to provide desirable color, taste,
stability, buffering capacity, dispersion or other known desirable
features are red iron oxide, silica gel, sodium lauryl sulfate,
titanium dioxide, edible white ink and the like. Similar diluents
can be used to make compressed tablets. Both tablets and capsules
can be manufactured as sustained release products to provide for
continuous release of medication over a period of hours. Compressed
tablets can be sugar coated or film coated to mask any unpleasant
taste and protect the tablet from the atmosphere, or enteric-coated
for selective disintegration in the gastrointestinal tract. Liquid
dosage forms for oral administration can contain coloring and
flavoring to increase patient acceptance.
Formulations suitable for buccal (sub-lingual) administration
include lozenges comprising the compound in a flavored base,
usually sucrose and acacia or tragacanth; and pastilles comprising
the compound in an inert base such as gelatin and glycerin or
sucrose and acacia.
Formulations of the present invention suitable for parenteral
administration comprise sterile aqueous and non-aqueous injection
solutions of the compound, which preparations are preferably
isotonic with the blood of the intended recipient. These
preparations can contain anti-oxidants, buffers, bacteriostats and
solutes which render the formulation isotonic with the blood of the
intended recipient. Aqueous and non-aqueous sterile suspensions can
include suspending agents and thickening agents. The formulations
can be presented in unit/dose or multi-dose containers, for example
sealed ampoules and vials, and can be stored in a freeze-dried
(lyophilized) condition requiring only the addition of the sterile
liquid carrier, for example, saline or water-for-injection
immediately prior to use.
Extemporaneous injection solutions and suspensions can be prepared
from sterile powders, granules and tablets of the kind previously
described. For example, in one aspect of the present invention,
there is provided an injectable, stable, sterile composition
comprising a compound of the invention, in a unit dosage form in a
sealed container. The compound or salt is provided in the form of a
lyophilizate which is capable of being reconstituted with a
suitable pharmaceutically acceptable carrier to form a liquid
composition suitable for injection thereof into a subject. The unit
dosage form typically comprises from about 10 mg to about 10 grams
of the compound or salt. When the compound or salt is substantially
water-insoluble, a sufficient amount of emulsifying agent which is
pharmaceutically acceptable can be employed in sufficient quantity
to emulsify the compound or salt in an aqueous carrier. One such
useful emulsifying agent is phosphatidyl choline.
Formulations suitable for rectal administration are preferably
presented as unit dose suppositories. These can be prepared by
admixing the compound with one or more conventional solid carriers,
for example, cocoa butter, and then shaping the resulting
mixture.
Formulations suitable for topical application to the skin
preferably take the form of an ointment, cream, lotion, paste, gel,
spray, aerosol, or oil. Carriers which can be used include
petroleum jelly, lanoline, polyethylene glycols, alcohols,
transdermal enhancers, and combinations of two or more thereof.
Formulations suitable for transdermal administration can be
presented as discrete patches adapted to remain in intimate contact
with the epidermis of the recipient for a prolonged period of time.
Formulations suitable for transdermal administration can also be
delivered by iontophoresis (see, for example, Tyle, Pharm. Res.
3:318 (1986)) and typically take the form of an optionally buffered
aqueous solution of the compound. Suitable formulations comprise
citrate or bis\tris buffer (pH 6) or ethanol/water and contain from
0.1 to 0.2M of the compound.
The compound can alternatively be formulated for nasal
administration or otherwise administered to the lungs of a subject
by any suitable means, e.g., administered by an aerosol suspension
of respirable particles comprising the compound, which the subject
inhales. The respirable particles can be liquid or solid. The term
"aerosol" includes any gas-borne suspended phase, which is capable
of being inhaled into the bronchioles or nasal passages.
Specifically, aerosol includes a gas-home suspension of droplets,
as can be produced in a metered dose inhaler or nebulizer, or in a
mist sprayer. Aerosol also includes a dry powder composition
suspended in air or other carrier gas, which can be delivered by
insufflation from an inhaler device, for example. See Ganderton
& Jones, Drug Delivery to the Respiratory Tract, Ellis Horwood
(1987); Gonda (1990) Critical Reviews in Therapeutic Drug Carrier
Systems 6:273-313; and Raeburn et al., J. Pharmacol. Toxicol. Meth.
27:143 (1992). Aerosols of liquid panicles comprising the compound
can be produced by any suitable means, such as with a
pressure-driven aerosol nebulizer or an ultrasonic nebulizer, as is
known to those of skill in the art. See, e.g., U.S. Pat. No.
4,501,729. Aerosols of solid particles comprising the compound can
likewise be produced with any solid particulate medicament aerosol
generator, by techniques known in the pharmaceutical art.
Alternatively, one can administer the compound in a local rather
than systemic manner, for example, in a depot or sustained-release
formulation.
Further, the present invention provides liposomal formulations of
the compounds disclosed herein and salts thereof. The technology
for forming liposomal suspensions is well known in the art. When
the compound or salt thereof is an aqueous-soluble salt, using
conventional liposome technology, the same can be incorporated into
lipid vesicles. In such an instance, due to the water solubility of
the compound or salt, the compound or salt will be substantially
entrained within the hydrophilic center or core of the liposomes.
The lipid layer employed can be of any conventional composition and
can either contain cholesterol or can be cholesterol-free. When the
compound or salt of interest is water-insoluble, again employing
conventional liposome formation technology, the salt can be
substantially entrained within the hydrophobic lipid bilayer which
forms the structure of the liposome. In either instance, the
liposomes which are produced can be reduced in size, as through the
use of standard sonication and homogenization techniques.
The liposomal formulations containing the compounds disclosed
herein or salts thereof, can be lyophilized to produce a
lyophilizate which can be reconstituted with a pharmaceutically
acceptable carrier, such as water, to regenerate a liposomal
suspension.
In the case of water-insoluble compounds, a pharmaceutical
composition can be prepared containing the water-insoluble
compound, such as for example, in an aqueous base emulsion. In such
an instance, the composition will contain a sufficient amount of
pharmaceutically acceptable emulsifying agent to emulsify the
desired amount of the compound. Particularly useful emulsifying
agents include phosphatidyl cholines and lecithin.
In particular embodiments, the compound is administered to the
subject in a therapeutically effective amount, as that term is
defined above. Dosages of pharmaceutically active compounds can be
determined by methods known in the art, see, e.g., Remington's
Pharmaceutical Sciences (Maack Publishing Co., Easton, Pa.). The
therapeutically effective dosage of any specific compound will vary
somewhat from compound to compound, and patient to patient, and
will depend upon the condition of the patient and the route of
delivery. As a general proposition, a dosage from about 0.001 to
about 50 mg/kg will have therapeutic efficacy, with all weights
being calculated based upon the weight of the compound, including
the cases where a salt is employed. Toxicity concerns at the higher
level can restrict intravenous dosages to a lower level such as up
to about 10 mg/kg, with all weights being calculated based upon the
weight of the compound, including the cases where a salt is
employed. A dosage from about 10 mg/kg to about 50 mg/kg can be
employed for oral administration. Typically, a dosage from about
0.5 mg/kg to 5 mg/kg can be employed for intramuscular injection.
Particular dosages are about 1 .mu.mol/kg to 50 .mu.mol/kg, and
more particularly to about 22 .mu.mol/kg and to 33 .mu.mol/kg of
the compound for intravenous or oral administration,
respectively.
In particular embodiments of the invention, more than one
administration (e.g., two, three, four, or more administrations)
can be employed over a variety of time intervals (e.g., hourly,
daily, weekly, monthly, etc.) to achieve therapeutic effects.
The present invention finds use in veterinary and medical
applications. Suitable subjects include both avians and mammals,
with mammals being preferred. The term "avian" as used herein
includes, but is not limited to, chickens, ducks, geese, quail,
turkeys, and pheasants. The term "mammal" as used herein includes,
but is not limited to, humans, bovines, ovines, caprines, equines,
felines, canines, lagomorphs, etc. Human subjects include neonates,
infants, juveniles, and adults. In other embodiments, the subject
is an animal model of cancer. In certain embodiments, the subject
has or is at risk for cancer.
The following examples are not intended to limit the scope of the
claims to the invention, but are rather intended to be exemplary of
certain embodiments. Any variations in the exemplified methods that
occur to the skilled artisan are intended to fall within the scope
of the present invention. As will be understood by one skilled in
the art, there are several embodiments and elements for each aspect
of the claimed invention, and all combinations of different
elements are hereby anticipated, so the specific combinations
exemplified herein are not to be construed as limitations in the
scope of the invention as claimed. If specific elements are removed
or added to the group of elements available in a combination, then
the group of elements is to be construed as having incorporated
such a change.
EXAMPLE 1
Mutant KRAS-Specific siRNAs
Methods: Novel mutant-specific siRNAs (MS siRNAs) were designed
based on previous literature that suggests a 3-mismatch tolerance
threshold for 19-nucleotide siRNA efficacy (Naito et al., Nucleic
Acids Res. 32:W124 (2004)). With two or fewer mismatches between
the sequence and the target gene, the siRNA is able to successfully
bind and knock-down expression of the gene of interest; however, at
and above the 3 mismatch threshold, the siRNA fails to recognize
the target, thus allowing for expression of the encoded protein.
Custom MS siRNAs were generated using open source softwares
provided by Sigma Aldrich, Life Technologies and Dharmacon to be
antisense to an artificial, hyper-mutated version of the WT KRAS
gene which never actually occurs in nature, with exactly 3 point
mutations corresponding to each of the most commonly occurring KRAS
mutants (G12C, G12D or G12V, and G13D). Thirty flanking nucleotides
were included upstream and downstream of these sites in the
artificial, hyper-mutated mRNA input (FIG. 1). Of note, siRNA
sequences were designed to target two different artificial mRNA
sequences; one that simultaneously contained specific missense
mutations in codons 12 (G12C and G12D) and 13 (G13D), and another
that simultaneously contained specific missense mutations in codons
12 (G12C and G12V) and 13 (G13D) (FIG. 1). The resultant sequence
is thus antisense with 3 mismatch errors to WT KRAS but only 2
mismatch errors to each of the 3 mutant KRAS alleles. Consequently,
it was hypothesized that these MS siRNAs will optimize the task of
targeting mutant KRAS while sparing the WT KRAS allele since the
sequence is below the 3 mismatch threshold for the former and above
for the latter. In addition, by introducing one mutation from each
of 3 different prevalent KRAS mutants in the custom sequence
design, the resultant siRNA has the added potential benefit of
simultaneously targeting several KRAS mutants rather than one.
Constructs containing the WT, G12C, G12D, G12V, or G13D KRAS gene
inserted into pBABE-puro retroviral expression vectors were
prepared. To expand the vector constructs, plasmids were added to
high efficiency competent E. coli cells and incubated in S.O.C.
media on a shaker at 37.degree. C. Cells were then plated on
ampicillin agarose plates and incubated at 37.degree. C. overnight.
Liquid cultures were prepared by picking and placing bacterial
colonies from the overnight plates into LB broth with 1 .mu.l/ml
carbocyclin and incubating overnight on a shaker at 37.degree. C.
Liquid cultures were performed in triplicate. Plasmid DNA from the
resultant turbid cultures was purified using a QIAprep Spin
Miniprep Kit (Qiagen). Successful plasmid expansion was confirmed
via restriction enzyme digest using BamHI and HindIII and gel
electrophoresis. Undigested plasmids from the Miniprep were further
expanded in LB Broth with 0.1 .mu.l/ml carbocyclin and then
purified using a QIAprep Spin Maxiprep Kit (Qiagen).
To produce retrovirus containing the pBABE-puro-KRAS plasmids,
9.times.10.sup.6 HEK 293T cells were seeded onto 6 cm cell culture
plates in 293T media (DMEM with 10% FBS and 1%
penicillin-streptomycin) and incubated at 37.degree. C., 5%
CO.sub.2. After 24 hours, plasmid DNA mixtures were prepared for
each pBABE-puro-KRAS plasmid by creating a mixture of 0.01
.mu.g/.mu.l plasmid construct and 0.01 .mu.g/.mu.l PCL10A pack
vector plasmid to OptiMEM media. In addition, a L2K mixture was
prepared by adding 0.05 .mu.g/.mu.l Lipofectamine 2000 (Thermo
Fisher Scientific) in OptiMEM media and incubating at room
temperature for 5 minutes. The L2K mixture was then combined 1:1
with each plasmid DNA mixture and incubated at room temperature for
20 minutes. Media was removed from the incubated cells, then 2 ml
of 293T media was added to each well along with 250 .mu.l of the
plasmid DNA/L2K mixture. After another 24 hours, the plasmid
DNA/L2K media was replaced with 293T media. After another 24 hours,
the resultant viral media was collected from the wells and replaced
with fresh 2931 media. Virus media was stored overnight on ice at
4.degree. C. After another 24 hours, media was collected again from
the wells and added to the previously stored virus. The mixture was
centrifuged at room temperature, then the supernatant was
collected. This process was repeated using mCherry and 293T media
instead of plasmid construct to produce mCherry and empty vector
virus, respectively.
To infect cells with KRAS plasmid, NIH 3T3 cells were harvested and
seeded at 100,000 per well in 6 well plates in complete media (DMEM
with 10% Colorado calf serum and 1% pen/strep). After 4-6 hours and
once the cells attached, the media was aspirated and 2 ml of
complete media with 10 .mu.l/ml polybrene along with 250 .mu.l of
viral media (WT, G12C, G12D, G12V, G13D, mCherry, and empty vector)
or complete media (negative controls) were added to each well.
Cells were centrifuged at 1500 g for 60 minutes at 30.degree. C.,
then incubated overnight at 37.degree. C. After 24 hours, wells
were aspirated and complete media was added to each well. After
another 24 hours, wells were aspirated and complete media with 2
.mu.g/ml puromycin was added. Media was replaced with puromycin
media every 24 hours until no living cells remained in the negative
control wells. Successful infection was further verified using
mCherry expression.
RNAi knockdown was induced in KRAS-infected NIH 3T3 cells plated at
a density of 60,000 cells per 500 .mu.l complete media per well in
24 well plates. Sequences for the scrambled control siRNA, as well
as positive controls (Seq #2 and #3, G12C and G12D siRNAs)
previously found to potently silence wild-type and mutant KRAS were
used as indicated in FIG. 1 (Fleming et al., Mol. Cancer Res. 3:413
(2005); Pecot et al., Mol. Cancer Ther. 13:2876 (2014)). Cells were
incubated in 5:1 mixture of complete media and serum-free media,
along with 20 nM siRNA (Sigma Aldrich) and Lipofectainine(R)
RNAiMAX transfection reagent (Thermo Fisher Scientific, 2:1 ratio
of transfection reagent to siRNA by volume) for 5 hours at
37.degree. C. in 5% CO.sub.2. Media was removed, and cells were
incubated in complete media only for another 19 hours before RNA
was collected and purified using a QIAprep Spin Miniprep Kit
Purified RNA from siRNA treatments was quantified using a
spectrophotometer, then reverse transcribed to cDNA using an
iScript.TM. cDNA Synthesis Kit (Bio-Rad). To quantify relative
expression levels of KRAS, RT-PCR reactions were performed by
monitoring real-time changes in fluorescent intensity of SYBR green
on the StepOnePlus.TM. Real-Time PCR System (Thermo Fisher
Scientific). Each sample was run in triple replicate. The
StepOnePlus.TM. was also used to obtain RQ values using the
.DELTA..DELTA.CT analysis to calculate .DELTA.Ct values by
comparing cycle threshold (Ct values) of KRAS to those of the
target reference gene, 18 s, then compare .DELTA.Ct values for each
siRNA to those of the NC siRNA. Error bars represent 1 standard
deviation. Data represents the result of one trial of two
biological replicates for WT and G12D and two trials of two
biological replicates for G12C, G12V, and G13D. Reverse
transfection experiments were performed in duplicate for each siRNA
for each cell line.
Results: To test the efficacy of mutant-specific KRAS silencing in
vitro, a panel of candidate MS KRAS siRNA sequences was tested for
their ability to knock-down KRAS expression in both WT and target
mutant KRAS-expressing cells. The 12CD13D_1 sequence was observed
to exhibit a sparing of WT KRAS expression (only 4% knock-down
compared to negative control siRNA) while knocking down G12C (50%),
G12D (82%), and G13D mutant KRAS (66%) (FIG. 2A). The sequence was
also unexpectedly noted to knock down G12V expression (58%).
Additionally, 12CD13D_2 and 12CD13D_4 were also found to exhibit WT
sparing and mutant knockdown. However, the former appeared to
exhibit less WT sparing than 12CD13D_1 and the latter less KRAS
knockdown in all cell lines (FIG. 2A). The remaining sequences
exhibited either low potency against mutant KRAS, high KRAS
knockdown in the WT KRAS cell line, or both (FIG. 2A).
In addition, G12C- and G12D-specific siRNA sequences (Fleming et
al., Mol. Cancer Res. 3:413 (2005)) were tested in order to compare
the efficacy of MS siRNA sequences against those previously
demonstrated to exhibit target-specificity. However, the
mutant-specificity of these sequences was not confirmed, and the
sequences did not exhibit the expected preferential knockdown of
G12C and G12D mutant KRAS, respectively, over the WT or other
mutant alleles (FIG. 2B).
KRAS siRNA sequences 12CD13D_1 and 12CD13D_4 were tested in a KRAS
G12D mutant lung cancer cell line. Using a control siRNA (Scr) and
two previously validated KRAS siRNAs (Seq #2 and #3), it was
demonstrated that customized, mutant specific KRAS siRNA sequences
12CD13D_1 and 12CD13D_4 are highly effective at silencing KRAS
protein expression (FIG. 3).
Testing all possible siRNA sequence permutations between our custom
siRNA sequences. In order to verify the best possible custom KRAS
siRNA sequences (leading sequences being 12CD13D_1 and 12CD13D_4),
a library of sequences (12CD13D_A thru 12CD13D_F) were tested that
incrementally move downstream between 12CD13D_1 and 12CD13D_4 (FIG.
4).
Following stable transduction of 3T3 cells with either wild-type
(WT) or mutant G12C, G12D, G12V and G13D human KRAS sequences, the
cells were transfected with KRAS siRNA sequences listed in FIG. 5.
Twenty-four hours after transfection, cells were lysed, RNA
collected and cDNA was made. Quantitative qPCR was performed for
KRAS using 18s as a house-keeping gene. It was found that the
leading 12CD13D_1 and 12CD13D_4 custom sequences were still the
best overall at silencing mutant KRAS, while the other possible
KRAS siRNA sequences ("A" thru "F") were less potent overall at
silencing the different KRAS mRNA sequences. On this experiment the
custom KRAS siRNA 12CD13D_4 sequence was best at sparing the WT
sequence.
Discussion: Although numerous efforts have been made to target
mutant KRAS, no direct inhibitors are currently in clinical use.
Moreover, most current small-molecule cancer therapeutics exhibit
low target specificity, resulting in adverse toxicity in
non-cancerous cells (Pecot et al., Nat. Rev. Cancer 11:59 (2011)).
Despite current headways in inhibiting downstream effectors in the
KRAS signaling pathway, KRAS remains an elusive target for drug
development (Cox et al., Nat. Rev. Drug Discov. 13:828 (2014)). As
such, this study investigated the efficacy of novel MS siRNA as a
means of selectively inhibiting expression of mutant KRAS.
Based on these preliminary findings, the 12CD13D_1 and 12CD13D_2
siRNA sequences were chosen as lead candidates for further
investigation as therapeutic agents because of their high
mutant-specificity and potency. To a lesser extent, 12CD13D_4 is
also a promising candidate; however, its low efficiency in knocking
down KRAS expression in mutant targets suggests that it may not be
effective as a clinically relevant therapeutic agent. By contrast,
the G12C- and G12D-specific siRNA do not appear to exhibit any sort
of sparing of the WT KRAS allele.
In addition, the low specificity of both sequences designed to
target the G12V rather than the G12D point mutation suggests a
greater tolerance for WT KRAS in G12V-targeting sequences.
These preliminary findings collectively suggest the viability of
novel MS siRNAs as a mutant-specific vehicle for silencing
oncogenic KRAS. With its potential as an effective payload with
mutant KRAS specificity, novel mutant-specific siRNAs present a
promising avenue of pursuit for drugging the formerly
"undruggable."
EXAMPLE 2
Antisense Oligonucleotides Targeted to Synthetic Mutant KRAS
A series of antisense oligonucleotide (ASO) sequences were created
that target a mutant KRAS of the invention comprising the mutations
G12C, G12D and G13D (SEQ ID NO:53) relative to the wild-type KRAS
sequence (SEQ ID NO:52) (FIG. 6 and Table 2). In FIG. 6, the black
bars represent nucleotides that have a 2'-methoxy-ethyl (MOE)
modification, while the gray regions represent the "Gapmer" that is
composed of DNA. The schematic is not to scale and the black bars
are composed of 5 flanking MOE-modified nucleotides on each side
while there is a 10 nucleotide Gapmer. The ASOs incorporate
phosphorothioate linkages (PS, designated by a "*") between all
nucleotides, a 10-nt Gapmer (underlined), and 5 flanking 2'-MOE
(methoxy-ethyl) modifications (bold). The ASOs were tested to
identify single-stranded RNA and/or DNA sequences that maintain the
ability to silence several KRAS mutations.
TABLE-US-00010 TABLE 2 ASO sequences ASO SEQ Num- ID ber Sequence
NO 1 T*C*A*T*A*A*G*C*T*C*C*A*A*C*T*A*C*C*A*C 54 2
G*T*C*A*T*A*A*G*C*T*C*C*A*A*C*T*A*C*C*A 55 3
C*G*T*C*A*T*A*A*G*C*T*C*C*A*A*C*T*A*C*C 56 4
A*C*G*T*C*A*T*A*A*G*C*T*C*C*A*A*C*T*A*C 57 5
T*A*C*G*T*C*A*T*A*A*G*C*T*C*C*A*A*C*T*A 58 6
C*T*A*C*G*T*C*A*T*A*A*G*C*T*C*C*A*A*C*T 59 7
C*C*T*A*C*G*T*C*A*T*A*A*G*C*T*C*C*A*A*C 60 8
G*C*C*T*A*C*G*T*C*A*T*A*A*G*C*T*C*C*A*A 61 9
T*G*C*C*T*A*C*G*T*C*A*T*A*A*G*C*T*C*C*A 62 10
T*T*G*C*C*T*A*C*G*T*C*A*T*A*A*G*C*T*C*C 63 11
C*T*T*G*C*C*T*A*C*G*T*C*A*T*A*A*G*C*T*C 64 12
T*C*T*T*G*C*C*T*A*C*G*T*C*A*T*A*A*C*C*T 65 13
C*T*C*T*T*G*C*C*T*A*C*G*T*C*A*T*A*A*G*C 66 14
A*C*T*C*T*T*G*C*C*T*A*C*G*T*C*A*T*A*A*G 67 15
C*A*C*T*C*T*T*G*C*C*T*A*C*G*T*C*A*T*A*A 68 16
G*C*A*C*T*C*T*T*G*C*C*T*A*C*G*T*C*A*T*A 69
Four separate A431 cell lines were engineered to remove expression
of wild-type KRAS and express one of the mutations G12C, G12D,
G13D, or G12V. Each cell line was treated with free ASOs at 1.1
.mu.M for 48 hours, and qPCR, was run. The results are shown in
FIG. 7. While several of the ASOs were demonstrated to silence one
or more of the mutations, it was found that ASO15 and ASO16 were
very potent at silencing all 4 of the most common KRAS
mutations.
Some of the top hits were re-evaluated, and again ASO15 and ASO16
were found to potently silence all 4 of the KRAS mutations in a
dose-responsive manner (FIG. 8). Cells were treated with free ASOs
at 1.1 .mu.M and 10 .mu.M for 48 hours, then qPCR was run for
mutant KRAS.
EXAMPLE 3
Modified ASO16 Sequences
Starting with the potent ASO16, modified versions were prepared to
identify ASOs with increased mutation specificity by targeting the
ASO to mutations that exist in nature, e.g., single mutations
(G12C, G12D, G12V, or G13D). Modifications included base
substitutions and the use of locked nucleic acids. The modified
sequences are shown in Table 3. The ASOs incorporates
phosphorothioate linkages (PS, designated by a "*") between all
nucleotides, a 10-nt Gapmer (underlined), and 5 flanking 2'-MOE
(methoxy-ethyl) modifications (bold). The last four sequences use a
single locked nucleic acid (LNA, denoted by "+" before the base) in
place of an MOE to increase melting temperatures at specific sites.
The LNA consists of .a methylene bridge connecting the 2' and 4'
carbons.
TABLE-US-00011 TABLE 3 Modified ASO16 sequences ASO SEQ Num- ID ber
Sequence NO 16 G*C*A*C*T*C*T*T*G*C*C*T*A*C*G*T*C*A*T*A 69 ASO16-
G*C*A*C*T*C*T*T*G*C*C*T*A*C*G*C*C*A*C*A 70 G12C ASO16-
G*C*A*C*T*C*T*T*G*C*C*T*A*C*G*C*C*A*T*C 71 G12D ASO16-
G*C*A*C*T*C*T*T*G*C*C*T*A*C*G*C*C*A*A*C 72 G12V ASO16-
G*C*A*C*T*C*T*T*G*C*C*T*A*C*G*T*C*A*C*C 73 G13D ASO16-
G*C*A*C*T*C*T*T*G*C*C*T*A*C*G*C*C*A*C*+A 74 G12C- LNA ASO16-
G*C*A*C*T*C*T*T*G*C*C*T*A*C*G*C*C*A*+T*C 75 G12D- LNA ASO16-
G*C*A*C*T*C*T*T*G*C*C*T*A*C*G*C*C*A*+A*C 76 G12V- LNA ASO16-
G*C*A*C*T*C*T*T*G*C*C*T*A*C*G*+T*C*A*C*C 77 G13D- LNA
The ASOs were tested on the A431 cell lines as described above. The
results are shown in FIG. 9. Improved potency for each KRAS
mutation was found for: 1) G12C using ASO16-G12C and ASO-G12C-LNA,
2) G12D using ASO16-G12D and ASO16-G12D-LNA, 3) G12V using
ASO16-G12V and ASO16-G12V-LNA and 4) G13D using ASO16-G13D and
ASO16-G13D-LNA. These results indicate that the increased mutation
specificity of these ASO sequences led to increased potency.
EXAMPLE 4
Fully Modified siRNA Sequences
Several of the ASOs targeted to single KRAS mutations described in
Example 3 were converted to siRNA molecules in an effort to
identify sequences that maximize the reduction of expression of
mutated sequences while sparing the wild-type KRAS sequence. These
siRNAs were then fully modified (FM) to minimize nuclease
degradation and immune stimulation. While these types of
modifications often attenuate the silencing activity of siRNAs, the
inventors have developed several fully modified siRNA sequences
that retain all or nearly all of their silencing activity compared
to unmodified siRNAs.
Table 4 lists the fully modified siRNA sequences that were
prepared.
Each of the siRNAs was tested in A431 cells engineered to either
express WT or the targeted KRAS mutation. For mutant expressing
A431 cells, the WT allele was deleted via CRISPR, so the expression
shown is only reflective of the mutant mRNA. Cells were transfected
with a low dose (20 nM) of negative control (NC) or the FM KRAS
siRNAs and qPCR for KRAS expression was run on RNA isolated 24
hours later.
For siRNAs targeting the G12C mutation, it was found that
D1-G12C-FM and D2-G12C-FM were both able to reduce mutant KRAS G12C
while spare the wild-type expression (FIG. 10). Notably, not all of
the siRNAs were equivalent in suppressing G12C KRAS or sparing
wild-type KRAS. As shown in FIG. 11, it was found that some
(hatched bars) mutant-specific (MS) iterations of the `parent` D1,
D2, and D4 sequences were more potent (panel 1). It was found that
several of the MS sequences more potently reduced the mutant over
WT sequences (see D1-G12C, D2-G12C, D4-G12C), unlike a pan-KRAS Seq
2 (panel 2). Finally, it was found that FM iterations of these MS
sequences showed retained silencing activity on mutant KRAS over WT
KRAS expression (e.g., D2-G12C-FM-F) (panel 3).
TABLE-US-00012 TABLE 4 Fully modified siRNA sequences Name Strand
Sequence (5'-3') SEQ ID NO D1-G12C-FM S
[mG]*[mA]*[mG][mC][mU][mU][2flG][mU][2flG][2flG][2flC][mG][mU-
][mA][mG][mG][mC][mA][mA][mG][mA] 78 AS
[mU]*[2flU]*[mG][mC][mC][2flU][mA][mC][mG][mC][mC][mA][mC][2flA][mA][2-
flG][mC][mU][mC]*[mC]*[mA] 79 D1-G12D-FM S
[mG]*[mA]*[mG][mC][mU][mG][2flA][mU][2flG][2flG][2flC][mG][mU-
][mA][mG][mG][mC][mA][mA][mG][mA] 80 AS
[mU]*[2flU]*[mG][mC][mC][2flU][mA][mC][mG][mC][mC][mA][mU][2flC][mA][2-
flG][mC][mU][mC]*[mC]*[mA] 81 D1-G13D-FM S
[mG]*[mA]*[mG][mC][mU][mG][2flG][mU][2flG][2flA][2flC][mG][mU-
][mA][mG][mG][mC][mA][mA][mG][mA] 82 AS
[mU]*[2flU]*[mG][mC][mC][2flU][mA][mC][mG][mU][mC][mA][mC][2flC][mA][2-
flG][mC][mU][mC]*[mC]*[mA] 83 D2-G12C-FM S
[mA]*[mG]*[mG][mU][mU][mG][2flA][mG][2flC][2flU][2flU][mG][mU-
][mG][mG][mC][mG][mU][mA][mG][mA] 84 AS
[mU]*[2flA]*[mC][mG][mC][2flC][mA][mC][mA][mA][mG][mC][mU][2flC][mC][2-
flA][mA][mC][mU]*[mA]*[mC] 85 D2-G12D-FM S
[mA]*[mG]*[mU][mU][mG][mG][2flA][mG][2flC][2flU][2flG][mA][mU-
][mG][mG][mC][mG][mU][mA][mG][mG] 86 AS
[mU]*[2flA]*[mC][mG][mC][2flC][mA][mU][mC][mA][mG][mC][mU][2flC][mC][2-
flA][mA][mC][mU]*[mA]*[mC] 87 D2-G13D-FM S
[mA]*[mG]*[mU][mU][mG][mG][2flA][mG][2flC][2flU][2flG][mG][mU-
][mG][mA][mC][mG][mU][mA][mG][mG] 88 AS
[mU]*[2flA]*[mC][mG][mU][2flC][mA][mC][mC][mA][mG][mC][mU][2flC][mC][2-
flA][mA][mC][mU]*[mA]*[mC] 89 D4-G13D-FM S
[mG]*[mG]*[mU][mA][mG][mU][2flU][mG][2flC][2flA][2flG][mC][mU-
][mG][mG][mU][mG][mA][mC][mG][mU] 90 AS
[mG]*[2flU]*[mC][mA][mC][2flC][mA][mG][mC][mU][mC][mC][mA][2flA][mC][2-
flU][mA][mC][mC]*[mA]*[mC] 91 D1-G12V-FM S
[mA]*[mG]*[mU][mU][mG][mG][2flA][mG][2flC][2flU][2flG][mU][mU-
][mG][mG][mC][mG][mU][mA][mG][mG] 92 AS
[mU]*[2flA]*[mC][mG][mC][2flC][mA][mA][mC][mA][mG][mC][mU][2flC][mC][2-
flA][mA][mC][mU]*[mA]*[mC] 93 D2-G12V-FM S
[mG]*[mA]*[mG][mC][mU][mG][2flU][mU][2flG][2flG][2flC][mG][mU-
][mA][mG][mG][mC][mA][mA][mG][mA] 94 AS
[mU]*[2flU]*[mG][mC][mC][2flU][mA][mC][mG][mC][mC][mA][mA][2flC][mA][2-
flG][mC][mU][mC]*[mC]*[mA] 95 D1-G12D-FM-F S
[mG]*[mA]*[mG][mC][mU][mG][2flA][mU][2flG][2flG][2flC][mG][-
mU][mA][mG][mG][mC][mA][mA][mG][mA] 96 AS
[mU]*[2flU]*[mG][mC][mC][2flU][mA][mC][mG][mC][mC][mA][2flU][2flC][mA]-
[2flG][mC][mU][mC]*[mC]*[mA] 97 D1-G13D-FM-F S
[mG]*[mA]*[mG][mC][mU][mG][2flG][mU][2flG][2flA][2flC][mG][-
mU][mA][mG][mG][mC][mA][mA][mG][mA] 98 AS
[mU]*[2flU]*[mG][mC][mC][2flU][mA][mC][mG][2flU][mC][mA][mC][2flC][mA]-
[2flG][mC][mU][mC]*[mC]*[mA] 99 D2-G12C-DM-F S
[mA]*[mG]*[mU][mU][mG][mG][2flA][mG][2flC][2flU][2flU][mG][-
mU][mG][mG][mC][mG][mU][mA][mG][mG] 100 AS
[mU]*[2flA]*[mC][mG][mC][2flC][mA][mC][2flA][mA][mG][mC][mU][2flC][mC]-
[2flA][mA][mC][mU]*[mA]*[mC] 101 D2-G12D-FM-F S
[mA]*[mG]*[mU][mU][mG][mG][2flA][mG][2flC][2flU][2flG][mA][-
mU][mG][mG][mC][mG][mU][mA][mG][mG] 102 AS
[mU]*[2flA]*[mC][mG][mC][2flC][mA][2flU][mC][mA][mG][mC][mU][2flC][mC]-
[2flA][mA][mC][mU]*[mA]*[mC] 103 D2-G13D-FM-F S
[mA]*[mG]*[mU][mU][mG][mG][2flA][mG][2flC][2flU][2flG][mG][-
mU][mG][mA][mC][mG][mU][mA][mG][mG] 104 AS
[mU]*[2flA]*[mC][mG][2flU][2flC][mA][mC][mC][mA][mG][mC][mU][2flC][mC]-
[2flA][mA][mC][mU]*[mA]*[mC] 105 D1-G12V-FM-F S
[mA]*[mG]*[mU][mU][mG][mG][2flA][mG][2flC][2flU][2flG][mU][-
mU][mG][mG][mC][mG][mU][mA][mG][mG] 106 AS
[mU]*[2flA]*[mC][mG][mC][2flC][mA][2flA][mC][mA][mG][mC][mU][2flC][mC]-
[2flA][mA][mC][mU]*[mA]*[mC] 107 D2-G12V-FM-F S
[mG]*[mA]*[mG][mC][mU][mG][2flU][mU][2flG][2flG][2flC][mG][-
mU][mA][mG][mG][mC][mA][mA][mG][mA] 108 AS
[mU]*[2flU]*[mG][mC][mC][2flU][mA][mC][mG][mC][mC][mA][2flA][2flC][mA]-
[2flG][mC][mA][mC]*[mC]*[mA] 109 Seq2-FM S
[mG]*[mU]*[mC][mU][mC][mU][2flU][mG][2flG][2flA][2flU][mA][mU][m-
U][mC][mU][mC][mG][mA] 110 AS
[mU]*[2flC]*[mG][mA][mG][2flA][mA][mU][mA][mU][mC][mC][mA][2flA][mG][2-
flA][mG][mA][mC]*[mC]*[mG] 111 Seq3-FM S
[mC]*[mA]*[mG][mC][mU][mA][2flA][mU][2flU][2flC][2flA][mG][mA][m-
A][mU][mC][mA][mU][mU] 112 AS
[mA]*[2flA]*[mU][mG][mA][2flU][mU][mC][mU][mG][mA][mA][mU][2flU][mA][2-
flG][mC][mU][mG]*[mU]*[mA] 113 S - sense strand AS - antisense
strand m - 2'-O-methyl on sugar moieties 2fl - 2'-fluoro on sugar
moieties * - phosphorothioate in between nucleotides
For siRNAs targeting the G12D mutation, it was found that
D1-G12D-FM, D2-G12D-FM and D2-G12D-FM-F were all able to reduce
mutant KRAS G12D (FIG. 12). D1-G12D-FM and D2-G12D-FM were also
able to spare WT expression (FIG. 12). Notably, not all of the
siRNAs were equivalent in suppressing G12D KRAS or sparing
wild-type KRAS. As shown in FIG. 13, it was found that some
(hatched bars) mutant-specific (MS) iterations of the `parent` D1,
D2 and D4 sequences were more potent (panel 1). It was found that
several of the MS sequences more potently reduced the mutant over
WT sequences (see D1-G12D), unlike a pan-KRAS Seq 2 (panel 2).
Finally, it was found that FM iterations of these MS sequences
showed retained silencing activity on mutant KRAS over WT KRAS
expression D1-G12D-FM and D2-G12D-FM) (panel 3).
For siRNAs targeting the G12V mutation, it was found that
V1-G12V-FM and V2-G12D-FM were able to reduce mutant KRAS G12V
while also able to spare WT expression (FIG. 14). Notably, not all
of the siRNAs were equivalent in suppressing G12D KRAS or sparing
wild-type KRAS. As shown in FIG. 1.5, it was found that some
(hatched bars) mutant-specific (MS) iterations of the `parent` D1,
D2 and D4 sequences were more potent (panel 1). It was found that
several of the MS sequences more potently reduced the mutant over
WT sequences (see D2-G12V), unlike a pan-KRAS Seq 2 (panel 2).
Finally, it was found that FM iterations of these MS sequences
showed retained silencing activity on mutant KRAS over WT KRAS
expression (e.g., D1-G12V-FM and D2-G-12V-FM) (panel 3).
For siRNAs targeting the G13D mutation, it was found that
D2-G13D-FM and D2-G13D-FM-F were able to reduce mutant KRAS G12D
(FIG. 16) D2-G12D-FM-F was also able to spare WT expression (FIG.
16). Notably, not all of the siRNAs were equivalent in suppressing
G12D KRAS or sparing wild-type KRAS. As shown in FIG. 17, it was
found that some (hatched bars) mutant-specific (MS) iterations of
the `parent` D1, D2 and D4 sequences were more potent (panel 1). It
was found that several of the MS sequences more potently reduced
the mutant over WT sequences (see D1-G13D and D4-G13D), unlike a
pan-KRAS Seq 2 (panel 2). Finally, it was found that FM iterations
of these MS sequences showed retained silencing activity on mutant
KRAS over WT KRAS expression (e.g., D2-G13D-FM and D2-G13D-FM-F)
(panel 3).
EXAMPLE 5
Additional Fully Modified siRNA Sequences
siRNAs comprising the sequence of SEQ ID NO:50 or SEQ ID NO:51 were
used as positive controls in the experiments described in Example
1. Fully modified versions of these siRNAs were prepared to test
their specificity and potency. The sequences of the FM siRNAs are
shown in Table 4. The HCT116 (colon cancer, KRAS G13D) and LU65
(lung cancer, KRAS G12C) cell lines were transfected with 20 nM of
either unmodified Seq2 or Seq3, or fully chemically modified (FM)
Seq2-FM or Seq3-FM siRNA sequences. Both Seq2-FM and Seq3-FM
surprisingly maintained full silencing of KRAS activity, especially
at 48 hours post-treatment (FIG. 18).
All publications, patents, and patent applications are herein
incorporated by reference to the same extent as if each individual
publication, patent, or patent application was specifically and
individually indicated to be incorporated by reference.
Although the foregoing invention has been described in some detail
by way of illustration and example for purposes of clarity of
understanding, it will be obvious that certain changes and
modifications may be practiced within the scope of the list of the
foregoing embodiments and the appended claims.
SEQUENCE LISTINGS
1
159119RNAArtificialsiRNA sequence 1gagcuuauga cguaggcaa
19219RNAArtificialsiRNA sequence 2aguuggagcu uaugacgua
19319RNAArtificialsiRNA sequence 3gguaguugga gcuuaugac
19419RNAArtificialsiRNA sequence 4guaguuggag cuuaugacg
19519RNAArtificialsiRNA sequence 5uaguuggagc uuaugacgu
19619RNAArtificialsiRNA sequence 6guuggagcuu augacguag
19719RNAArtificialsiRNA sequence 7uuggagcuua ugacguagg
19819RNAArtificialsiRNA sequence 8uggagcuuau gacguaggc
19919RNAArtificialsiRNA sequence 9ggagcuuaug acguaggca
191021RNAArtificialsiRNA sequencemisc_feature(20)..(21)n is dT
10gagcuuauga cguaggcaan n 211121RNAArtificialsiRNA
sequencemisc_feature(20)..(21)n is dT 11aguuggagcu uaugacguan n
211221RNAArtificialsiRNA sequencemisc_feature(20)..(21)n is dT
12gguaguugga gcuuaugacn n 211321RNAArtificialsiRNA
sequencemisc_feature(20)..(21)n is dT 13guaguuggag cuuaugacgn n
211421RNAArtificialsiRNA sequencemisc_feature(20)..(21)n is dT
14uaguuggagc uuaugacgun n 211521RNAArtificialsiRNA
sequencemisc_feature(20)..(21)n is dT 15guuggagcuu augacguagn n
211621RNAArtificialsiRNA sequencemisc_feature(20)..(21)n is dT
16uuggagcuua ugacguaggn n 211721RNAArtificialsiRNA
sequencemisc_feature(20)..(21)n is dT 17uggagcuuau gacguaggcn n
211821RNAArtificialsiRNA sequencemisc_feature(20)..(21)n is dT
18ggagcuuaug acguaggcan n 211919RNAArtificialsiRNA sequence
19uugccuacgu cauaagcuc 192019RNAArtificialsiRNA sequence
20uacgucauaa gcuccaacu 192119RNAArtificialsiRNA sequence
21gucauaagcu ccaacuacc 192219RNAArtificialsiRNA sequence
22cgucauaagc uccaacuac 192319RNAArtificialsiRNA sequence
23acgucauaag cuccaacua 192419RNAArtificialsiRNA sequence
24cuacgucaua agcuccaac 192519RNAArtificialsiRNA sequence
25ccuacgucau aagcuccaa 192619RNAArtificialsiRNA sequence
26gccuacguca uaagcucca 192719RNAArtificialsiRNA sequence
27ugccuacguc auaagcucc 192821RNAArtificialsiRNA
sequencemisc_feature(20)..(21)n is dT 28uugccuacgu cauaagcucn n
212921RNAArtificialsiRNA sequencemisc_feature(20)..(21)n is dT
29uacgucauaa gcuccaacun n 213021RNAArtificialsiRNA
sequencemisc_feature(20)..(21)n is dT 30gucauaagcu ccaacuaccn n
213121RNAArtificialsiRNA sequencemisc_feature(20)..(21)n is dT
31cgucauaagc uccaacuacn n 213221RNAArtificialsiRNA
sequencemisc_feature(20)..(21)n is dT 32acgucauaag cuccaacuan n
213321RNAArtificialsiRNA sequencemisc_feature(20)..(21)n is dT
33cuacgucaua agcuccaacn n 213421RNAArtificialsiRNA
sequencemisc_feature(20)..(21)n is dT 34ccuacgucau aagcuccaan n
213521RNAArtificialsiRNA sequencemisc_feature(20)..(21)n is dT
35gccuacguca uaagcuccan n 213621RNAArtificialsiRNA
sequencemisc_feature(20)..(21)n is dT 36ugccuacguc auaagcuccn n
213763DNAArtificialMutated human KRAS gene sequence 37actgaatata
aacttgtggt agttggagct tatgacgtag gcaagagtgc cttgacgata 60cag
633863DNAArtificialMutated human KRAS gene sequence 38actgaatata
aacttgtggt agttggagct tttgacgtag gcaagagtgc cttgacgata 60cag
633963DNAArtificialMutated human KRAS gene sequence 39actgaatata
aacttgtggt agttggagct ggtggcgtag gcaagagtgc cttgacgata 60cag
634063DNAHomo sapiens 40actgaatata aacttgtggt agttggagct ggtggcgtag
gcaagagtgc cttgacgata 60cag 634163DNAArtificialMutated human KRAS
gene sequence 41actgaatata aacttgtggt agttggagct tgtggcgtag
gcaagagtgc cttgacgata 60cag 634263DNAArtificialMutated human KRAS
gene sequence 42actgaatata aacttgtggt agttggagct gatggcgtag
gcaagagtgc cttgacgata 60cag 634363DNAArtificialMutated human KRAS
gene sequence 43actgaatata aacttgtggt agttggagct gttggcgtag
gcaagagtgc cttgacgata 60cag 634463DNAArtificialMutated human KRAS
gene sequence 44actgaatata aacttgtggt agttggagct ggtgacgtag
gcaagagtgc cttgacgata 60cag 634563RNAArtificialMutated siRNA target
sequencemisc_feature(22)..(40)G12C siRNA target sequence
45acugaauaua aacuuguggu aguuggagcu uguggcguag gcaagagugc cuugacgaua
60cag 634663RNAArtificialMutated siRNA target
sequencemisc_feature(22)..(40)G12D siRNA target sequence
46acugaauaua aacuuguggu aguuggagcu gauggcguag gcaagagugc cuugacgaua
60cag 634763RNAArtificialMutated siRNA target
sequencemisc_feature(18)..(36)12CD13D_4 siRNA target
sequencemisc_feature(19)..(37)12CD13D_A target
sequencemisc_feature(20)..(38)12CD13D_B target
sequencemisc_feature(21)..(39)12CD13D_2 siRNA target
sequencemisc_feature(22)..(40)12CD13D_C target
sequencemisc_feature(23)..(41)12CD13D_D target
sequencemisc_feature(24)..(42)12CD13D_E target
sequencemisc_feature(25)..(43)12CD13D_F target
sequencemisc_feature(26)..(44)12CD13D_1 siRNA target
sequencemisc_feature(28)..(46)12CD13D_3 siRNA target sequence
47acugaauaua aacuuguggu aguuggagcu uaugacguag gcaagagugc cuugacgaua
60cag 634863RNAArtificialMutated siRNA target
sequencemisc_feature(21)..(39)12CV13D_1 siRNA target
sequencemisc_feature(26)..(44)12CV13D_2 siRNA target sequence
48acugaauaua aacuuguggu aguuggagcu uuugacguag gcaagagugc cuugacgaua
60cag 634919RNAArtificialNegative control siRNA sequence
49uucuccgaac gugucacgu 195019RNAArtificialPositive control siRNA
sequence 50gucucuugga uauucucga 195119RNAArtificialPositive control
siRNA sequence 51cagcuaauuc agaaucauu 195241RNAHomo sapiens
52cuugugguag uuggagcugg uggcguaggc aagagugccu u
415341RNAArtificialsynthetic mutant KRAS 53cuugugguag uuggagcuua
ugacguaggc aagagugccu u 415420DNAArtificialantisense
oligonucleotidemisc_feature(1)..(5)2'-methoxyethyl group on each
nucleotidemisc_feature(16)..(20)2'-methoxyethyl group on each
nucleotide 54tcataagctc caactaccac 205520DNAArtificialantisense
oligonucleotidemisc_feature(1)..(5)2'-methoxyethyl group on each
nucleotidemisc_feature(16)..(20)2'-methoxyethyl group on each
nucleotide 55gtcataagct ccaactacca 205620DNAArtificialantisense
oligonucleotidemisc_feature(1)..(5)2'-methoxyethyl group on each
nucleotidemisc_feature(16)..(20)2'-methoxyethyl group on each
nucleotide 56cgtcataagc tccaactacc 205720DNAArtificialantisense
oligonucleotidemisc_feature(1)..(5)2'-methoxyethyl group on each
nucleotidemisc_feature(6)..(20)2'-methoxyethyl group on each
nucleotide 57acgtcataag ctccaactac 205820DNAArtificialantisense
oligonucleotidemisc_feature(1)..(5)2'-methoxyethyl group on each
nucleotidemisc_feature(16)..(20)2'-methoxyethyl group on each
nucleotide 58tacgtcataa gctccaacta 205920DNAArtificialantisense
oligonucleotidemisc_feature(1)..(5)2'-methoxyethyl group on each
nucleotidemisc_feature(16)..(20)2'-methoxyethyl group on each
nucleotide 59ctacgtcata agctccaact 206020DNAArtificialantisense
oligonucleotidemisc_feature(1)..(5)2'-methoxyethyl group on each
nucleotidemisc_feature(16)..(20)2'-methoxyethyl group on each
nucleotide 60cctacgtcat aagctccaac 206120DNAArtificialantisense
oligonucleotidemisc_feature(1)..(5)2'-methoxyethyl group on each
nucleotidemisc_feature(16)..(20)2'-methoxyethyl group on each
nucleotide 61gcctacgtca taagctccaa 206220DNAArtificialantisense
oligonucleotidemisc_feature(1)..(5)2'-methoxyethyl group on each
nucleotidemisc_feature(16)..(20)2'-methoxyethyl group on each
nucleotide 62tgcctacgtc ataagctcca 206320DNAArtificialantisense
oligonucleotidemisc_feature(1)..(5)2'-methoxyethyl group on each
nucleotidemisc_feature(16)..(20)2'-methoxyethyl group on each
nucleotide 63ttgcctacgt cataagctcc 206420DNAArtificialantisense
oligonucleotidemisc_feature(1)..(5)2'-methoxyethyl group on each
nucleotidemisc_feature(16)..(20)2'-methoxyethyl group on each
nucleotide 64cttgcctacg tcataagctc 206520DNAArtificialantisense
oligonucleotidemisc_feature(1)..(5)2'-methoxyethyl group on each
nucleotidemisc_feature(16)..(20)2'-methoxyethyl group on each
nucleotide 65tcttgcctac gtcataagct 206620DNAArtificialantisense
oligonucleotidemisc_feature(1)..(5)2'-methoxyethyl group on each
nucleotidemisc_feature(16)..(20)2'-methoxyethyl group on each
nucleotide 66ctcttgccta cgtcataagc 206720DNAArtificialantisense
oligonucleotidemisc_feature(1)..(5)2'-methoxyethyl group on each
nucleotidemisc_feature(16)..(20)2'-methoxyethyl group on each
nucleotide 67actcttgcct acgtcataag 206820DNAArtificialantisense
oligonucleotidemisc_feature(1)..(5)2'-methoxyethyl group on each
nucleotidemisc_feature(16)..(20)2'-methoxyethyl group on each
nucleotide 68cactcttgcc tacgtcataa 206920DNAArtificialantisense
oligonucleotidemisc_feature(1)..(5)2'-methoxyethyl group on each
nucleotidemisc_feature(16)..(20)2'-methoxyethyl group on each
nucleotide 69gcactcttgc ctacgtcata 207020DNAArtificialantisense
oligonucleotidemisc_feature(1)..(5)2'-methoxyethyl group on each
nucleotidemisc_feature(16)..(20)2'-methoxyethyl group on each
nucleotide 70gcactcttgc ctacgccaca 207120DNAArtificialantisense
oligonucleotidemisc_feature(1)..(5)2'-methoxyethyl group on each
nucleotidemisc_feature(16)..(20)2'-methoxyethyl group on each
nucleotide 71gcactcttgc ctacgccatc 207220DNAArtificialantisense
oligonucleotidemisc_feature(1)..(5)2'-methoxyethyl group on each
nucleotidemisc_feature(16)..(20)2'-methoxyethyl group on each
nucleotide 72gcactcttgc ctacgccaac 207320DNAArtificialantisense
oligonucleotidemisc_feature(1)..(5)2'-methoxyethyl group on each
nucleotidemisc_feature(16)..(20)2'-methoxyethyl group on each
nucleotide 73gcactcttgc ctacgtcacc 207420DNAArtificialantisense
oligonucleotidemisc_feature(1)..(5)2'-methoxyethyl group on each
nucleotidemisc_feature(16)..(19)2'-methoxyethyl group on each
nucleotidemisc_feature(20)..(20)2', 4' methylene bridge
74gcactcttgc ctacgccaca 207520DNAArtificialantisense
oligonucleotidemisc_feature(1)..(5)2'-methoxyethyl group on each
nucleotidemisc_feature(16)..(18)2'-methoxyethyl group on each
nucleotidemisc_feature(19)..(19)2', 4' methylene
bridgemisc_feature(20)..(20)2'-methoxyethyl group 75gcactcttgc
ctacgccatc 207620DNAArtificialantisense
oligonucleotidemisc_feature(1)..(5)2'-methoxyethyl group on each
nucleotidemisc_feature(16)..(18)2'-methoxyethyl group on each
nucleotidemisc_feature(19)..(19)2', 4' methylene
bridgemisc_feature(20)..(20)2'-methoxyethyl group 76gcactcttgc
ctacgccaac 207720DNAArtificialantisense
oligonucleotidemisc_feature(1)..(5)2'-methoxyethyl group on each
nucleotidemisc_feature(16)..(16)2', 4' methylene
bridgemisc_feature(17)..(20)2'-methoxyethyl group on each
nucleotide 77gcactcttgc ctacgtcacc 207821RNAArtificialsiRNA sense
strandmisc_feature(1)..(6)2'-O-methyl group on each
nucleotidemisc_feature(7)..(7)2'-fluoro
groupmisc_feature(8)..(8)2'-O-methyl
groupmisc_feature(9)..(11)2'-fluoro group on each
nucleotidemisc_feature(12)..(21)2'-O-methyl group on each
nucleotide 78gagcuugugg cguaggcaag a 217921RNAArtificialsiRNA
antisense strandmisc_feature(1)..(1)2'-O-methyl
groupmisc_feature(2)..(2)2'-fluoro
groupmisc_feature(3)..(5)2'-O-methyl group on each
nucleotidemisc_feature(6)..(6)2'-fluoro
groupmisc_feature(7)..(13)2'-O-methyl group on each
nucleotidemisc_feature(14)..(14)2'-fluoro
groupmisc_feature(15)..(15)2'-O-methyl
groupmisc_feature(16)..(16)2'-fluoro
groupmisc_feature(17)..(21)2'-O-methyl group on each nucleotide
79uugccuacgc cacaagcucc a 218021RNAArtificialsiRNA sense
strandmisc_feature(1)..(6)2'-O-methyl group on each
nucleotidemisc_feature(7)..(7)2'-fluoro
groupmisc_feature(8)..(8)2'-O-methyl
groupmisc_feature(9)..(11)2'-fluoro group on each
nucleotidemisc_feature(12)..(21)2'-O-methyl group on each
nucleotide 80gagcugaugg cguaggcaag a 218121RNAArtificialsiRNA
antisense strandmisc_feature(1)..(1)2'-O-methyl
groupmisc_feature(2)..(2)2'-fluoro
groupmisc_feature(3)..(5)2'-O-methyl group on each
nucleotidemisc_feature(6)..(6)2'-fluoro
groupmisc_feature(7)..(13)2'-O-methyl group on each
nucleotidemisc_feature(14)..(14)2'-fluoro
groupmisc_feature(15)..(15)2'-O-methyl
groupmisc_feature(16)..(16)2'-fluoro
groupmisc_feature(17)..(21)2'-O-methyl group on each nucleotide
81uugccuacgc caucagcucc a 218221RNAArtificialsiRNA sense
strandmisc_feature(1)..(6)2'-O-methyl group on each
nucleotidemisc_feature(7)..(7)2'-fluoro
groupmisc_feature(8)..(8)2'-O-methyl
groupmisc_feature(9)..(11)2'-fluoro group on each
nucleotidemisc_feature(12)..(21)2'-O-methyl group on each
nucleotide 82gagcugguga cguaggcaag a 218321RNAArtificialsiRNA
antisense strandmisc_feature(1)..(1)2'-O-methyl
groupmisc_feature(2)..(2)2'-fluoro
groupmisc_feature(3)..(5)2'-O-methyl group on each
nucleotidemisc_feature(6)..(6)2'-fluoro
groupmisc_feature(7)..(13)2'-O-methyl group on each
nucleotidemisc_feature(14)..(14)2'-fluoro
groupmisc_feature(15)..(15)2'-O-methyl
groupmisc_feature(16)..(16)2'-fluoro
groupmisc_feature(17)..(21)2'-O-methyl group on each nucleotide
83uugccuacgu caccagcucc a 218421RNAArtificialsiRNA sense
strandmisc_feature(1)..(6)2'-O-methyl group on each
nucleotidemisc_feature(7)..(7)2'-fluoro
groupmisc_feature(8)..(8)2'-O-methyl
groupmisc_feature(9)..(11)2'-fluoro group on each
nucleotidemisc_feature(12)..(21)2'-O-methyl group on each
nucleotide 84aguuggagcu uguggcguag g 218521RNAArtificialsiRNA
antisense strandmisc_feature(1)..(1)2'-O-methyl
groupmisc_feature(2)..(2)2'-fluoro
groupmisc_feature(3)..(5)2'-O-methyl group on each
nucleotidemisc_feature(6)..(6)2'-fluoro
groupmisc_feature(7)..(13)2'-O-methyl group on each
nucleotidemisc_feature(14)..(14)2'-fluoro
groupmisc_feature(15)..(15)2'-O-methyl
groupmisc_feature(16)..(16)2'-fluoro
groupmisc_feature(17)..(21)2'-O-methyl group on each nucleotide
85uacgccacaa gcuccaacua c 218621RNAArtificialsiRNA sense
strandmisc_feature(1)..(6)2'-O-methyl group on each
nucleotidemisc_feature(7)..(7)2'-fluoro
groupmisc_feature(8)..(8)2-O-methyl
groupmisc_feature(9)..(11)2'-fluoro group on each
nucleotidemisc_feature(12)..(21)2-O-methyl group on each nucleotide
86aguuggagcu gauggcguag g 218721RNAArtificialsiRNA antisense
strandmisc_feature(1)..(1)2-O-methyl
groupmisc_feature(2)..(2)2'-fluoro
groupmisc_feature(3)..(5)2-O-methyl group on each
nucleotidemisc_feature(6)..(6)2'-fluoro
groupmisc_feature(7)..(13)2-O-methyl group on each
nucleotidemisc_feature(14)..(14)2'-fluoro
groupmisc_feature(15)..(15)2-O-methyl
groupmisc_feature(16)..(16)2'-fluoro
groupmisc_feature(17)..(21)2-O-methyl group on each nucleotide
87uacgccauca gcuccaacua c 218821RNAArtificialsiRNA sense
strandmisc_feature(1)..(6)2-O-methyl group on each
nucleotidemisc_feature(7)..(7)2'-fluoro
groupmisc_feature(8)..(8)2-O-methyl
groupmisc_feature(9)..(11)2'-fluoro group on each
nucleotidemisc_feature(12)..(21)2-O-methyl group on each nucleotide
88aguuggagcu ggugacguag g 218921RNAArtificialsiRNA antisense
strandmisc_feature(1)..(1)2'-O-methyl
groupmisc_feature(2)..(2)2'-fluoro
groupmisc_feature(3)..(5)2-O-methyl group on each
nucleotidemisc_feature(6)..(6)2'-fluoro
groupmisc_feature(7)..(13)2'-O-methyl group on each
nucleotidemisc_feature(14)..(14)2'-fluoro
groupmisc_feature(15)..(15)2'-O-methyl
groupmisc_feature(16)..(16)2'-fluoro
groupmisc_feature(17)..(21)2'-O-methyl group on each nucleotide
89uacgucacca gcuccaacua c 219021RNAArtificialsiRNA sense
strandmisc_feature(1)..(6)2'-O-methyl group on each
nucleotidemisc_feature(7)..(7)2'-fluoro
groupmisc_feature(8)..(8)2'-O-methyl
groupmisc_feature(9)..(11)2'-fluoro group on each
nucleotidemisc_feature(12)..(21)2'-O-methyl group on each
nucleotide 90gguaguugga gcuggugacg u 219121RNAArtificialsiRNA
antisense strandmisc_feature(1)..(1)2'-O-methyl
groupmisc_feature(2)..(2)2'-fluoro
groupmisc_feature(3)..(5)2'-O-methyl group on each
nucleotidemisc_feature(6)..(6)2'-fluoro
groupmisc_feature(7)..(13)2'-O-methyl group on each
nucleotidemisc_feature(14)..(14)2'-fluoro
groupmisc_feature(15)..(15)2'-O-methyl
groupmisc_feature(16)..(16)2'-fluoro
groupmisc_feature(17)..(21)2'-O-methyl group on each nucleotide
91gucaccagcu ccaacuacca c 219221RNAArtificialsiRNA sense
strandmisc_feature(1)..(6)2'-O-methyl group on each
nucleotidemisc_feature(7)..(7)2'-fluoro
groupmisc_feature(8)..(8)2'-O-methyl
groupmisc_feature(9)..(11)2'-fluoro group on each
nucleotidemisc_feature(12)..(21)2'-O-methyl group on each
nucleotide 92aguuggagcu guuggcguag g 219321RNAArtificialsiRNA
antisense strandmisc_feature(1)..(1)2'-O-methyl
groupmisc_feature(2)..(2)2'-fluoro
groupmisc_feature(3)..(5)2'-O-methyl group on each
nucleotidemisc_feature(6)..(6)2'-fluoro
groupmisc_feature(7)..(13)2'-O-methyl group on each
nucleotidemisc_feature(14)..(14)2'-fluoro
groupmisc_feature(15)..(15)2'-O-methyl
groupmisc_feature(16)..(16)2'-fluoro
groupmisc_feature(17)..(21)2'-O-methyl group on each nucleotide
93uacgccaaca gcuccaacua c 219421RNAArtificialsiRNA sense
strandmisc_feature(1)..(6)2'-O-methyl group on each
nucleotidemisc_feature(7)..(7)2'-fluoro
groupmisc_feature(8)..(8)2'-O-methyl
groupmisc_feature(9)..(11)2'-fluoro group on each
nucleotidemisc_feature(12)..(21)2'-O-methyl group on each
nucleotide 94gagcuguugg cguaggcaag a 219521RNAArtificialsiRNA
antisense strandmisc_feature(1)..(1)2'-O-methyl
groupmisc_feature(2)..(2)2'-fluoro
groupmisc_feature(3)..(5)2'-O-methyl group on each
nucleotidemisc_feature(6)..(6)2'-fluoro
groupmisc_feature(7)..(13)2'-O-methyl group on each
nucleotidemisc_feature(14)..(14)2'-fluoro
groupmisc_feature(15)..(15)2'-O-methyl
groupmisc_feature(16)..(16)2'-fluoro
groupmisc_feature(17)..(21)2'-O-methyl group on each nucleotide
95uugccuacgc caacagcucc a 219621RNAArtificialsiRNA sense
strandmisc_feature(1)..(6)2'-O-methyl group on each
nucleotidemisc_feature(7)..(7)2'-fluoro
groupmisc_feature(8)..(8)2'-O-methyl
groupmisc_feature(9)..(11)2'-fluoro group on each
nucleotidemisc_feature(12)..(21)2'-O-methyl group on each
nucleotide 96gagcugaugg cguaggcaag a 219721RNAArtificialsiRNA
antisense strandmisc_feature(1)..(1)2'-O-methyl
groupmisc_feature(2)..(2)2'-fluoro
groupmisc_feature(3)..(5)2'-O-methyl group on each
nucleotidemisc_feature(6)..(6)2'-fluoro
groupmisc_feature(7)..(12)2'-O-methyl group on each
nucleotidemisc_feature(13)..(14)2'-fluoro group on each
nucleotidemisc_feature(15)..(15)2'-O-methyl
groupmisc_feature(16)..(16)2'-fluoro
groupmisc_feature(17)..(21)2'-O-methyl group on each nucleotide
97uugccuacgc caucagcucc a 219821RNAArtificialsiRNA sense
strandmisc_feature(1)..(6)2'-O-methyl group on each
nucleotidemisc_feature(7)..(7)2'-fluoro
groupmisc_feature(8)..(8)2'-O-methyl
groupmisc_feature(9)..(11)2'-fluoro group on each
nucleotidemisc_feature(12)..(21)2'-O-methyl group on each
nucleotide 98gagcugguga cguaggcaag a 219921RNAArtificialsiRNA
antisense strandmisc_feature(1)..(1)2'-O-methyl
groupmisc_feature(2)..(2)2'-fluoro
groupmisc_feature(3)..(5)2'-O-methyl group on each
nucleotidemisc_feature(6)..(6)2'-fluoro
groupmisc_feature(7)..(9)2'-O-methyl group on each
nucleotidemisc_feature(10)..(10)2'-fluoro
groupmisc_feature(11)..(13)2'-O-methyl group on each
nucleotidemisc_feature(14)..(14)2'-fluoro
groupmisc_feature(15)..(15)2'-O-methyl
groupmisc_feature(16)..(16)2'-fluoro
groupmisc_feature(17)..(21)2'-O-methyl group on each nucleotide
99uugccuacgu caccagcucc a 2110021RNAArtificialsiRNA sense
strandmisc_feature(1)..(6)2'-O-methyl group on each
nucleotidemisc_feature(7)..(7)2'-fluoro
groupmisc_feature(8)..(8)2'-O-methyl
groupmisc_feature(9)..(11)2'-fluoro group on each
nucleotidemisc_feature(12)..(21)2'-O-methyl group on each
nucleotide 100aguuggagcu uguggcguag g 2110121RNAArtificialsiRNA
antisense strandmisc_feature(1)..(1)2'-O-methyl
groupmisc_feature(2)..(2)2'-fluoro
groupmisc_feature(3)..(5)2'-O-methyl group on each
nucleotidemisc_feature(6)..(6)2'-fluoro
groupmisc_feature(7)..(8)2'-O-methyl group on each
nucleotidemisc_feature(9)..(9)2'-fluoro
groupmisc_feature(10)..(13)2'-O-methyl group on each
nucleotidemisc_feature(14)..(14)2'-fluoro
groupmisc_feature(15)..(15)2'-O-methyl
groupmisc_feature(16)..(16)2'-fluoro
groupmisc_feature(17)..(21)2'-O-methyl group on each nucleotide
101uacgccacaa gcuccaacua c 2110221RNAArtificialsiRNA sense
strandmisc_feature(1)..(6)2'-O-methyl group on each
nucleotidemisc_feature(7)..(7)2'-fluoro
groupmisc_feature(8)..(8)2'-O-methyl
groupmisc_feature(9)..(11)2'-fluoro group on each
nucleotidemisc_feature(12)..(21)2'-O-methyl group on each
nucleotide 102aguuggagcu gauggcguag g 2110321RNAArtificialsiRNA
antisense strandmisc_feature(1)..(1)2'-O-methyl
groupmisc_feature(2)..(2)2'-fluoro
groupmisc_feature(3)..(5)2'-O-methyl group on each
nucleotidemisc_feature(6)..(6)2'-fluoro
groupmisc_feature(7)..(7)2'-O-methyl
groupmisc_feature(8)..(8)2'-fluoro
groupmisc_feature(9)..(13)2'-O-methyl group on each
nucleotidemisc_feature(14)..(14)2'-fluoro
groupmisc_feature(15)..(15)2'-O-methyl
groupmisc_feature(16)..(16)2'-fluoro
groupmisc_feature(17)..(21)2'-O-methyl group on each nucleotide
103uacgccauca gcuccaacua c 2110421RNAArtificialsiRNA sense
strandmisc_feature(1)..(6)2'-O-methyl group on each
nucleotidemisc_feature(7)..(7)2'-fluoro
groupmisc_feature(8)..(8)2'-O-methyl
groupmisc_feature(9)..(11)2'-fluoro group on each
nucleotidemisc_feature(12)..(21)2'-O-methyl group on each
nucleotide 104aguuggagcu ggugacguag g 2110521RNAArtificialsiRNA
antisense strandmisc_feature(1)..(1)2'-O-methyl
groupmisc_feature(2)..(2)2'-fluoro
groupmisc_feature(3)..(4)2'-O-methyl group on each
nucleotidemisc_feature(5)..(6)2'-fluoro group on each
nucleotidemisc_feature(7)..(13)2'-O-methyl group on each
nucleotidemisc_feature(14)..(14)2'-fluoro
groupmisc_feature(15)..(15)2'-O-methyl
groupmisc_feature(16)..(16)2'-fluoro
groupmisc_feature(17)..(21)2'-O-methyl group on each nucleotide
105uacgucacca gcuccaacua c 2110621RNAArtificialsiRNA sense
strandmisc_feature(1)..(6)2'-O-methyl group on each
nucleotidemisc_feature(7)..(7)2'-fluoro
groupmisc_feature(8)..(8)2'-O-methyl
groupmisc_feature(9)..(11)2'-fluoro group on each
nucleotidemisc_feature(12)..(21)2'-O-methyl group on each
nucleotide 106aguuggagcu guuggcguag g 2110721RNAArtificialsiRNA
antisense strandmisc_feature(1)..(1)2'-O-methyl
groupmisc_feature(2)..(2)2'-fluoro
groupmisc_feature(3)..(5)2'-O-methyl group on each
nucleotidemisc_feature(6)..(6)2'-fluoro
groupmisc_feature(7)..(7)2'-O-methyl
groupmisc_feature(8)..(8)2'-fluoro
groupmisc_feature(9)..(13)2'-O-methyl group on each
nucleotidemisc_feature(14)..(14)2'-fluoro
groupmisc_feature(15)..(15)2'-O-methyl
groupmisc_feature(16)..(16)2'-fluoro
groupmisc_feature(17)..(21)2'-O-methyl group on each nucleotide
107uacgccaaca gcuccaacua c 2110821RNAArtificialsiRNA sense
strandmisc_feature(1)..(6)2'-O-methyl group on each
nucleotidemisc_feature(7)..(7)2'-fluoro
groupmisc_feature(8)..(8)2'-O-methyl
groupmisc_feature(9)..(11)2'-fluoro group on each
nucleotidemisc_feature(12)..(21)2'-O-methyl group on each
nucleotide 108gagcuguugg cguaggcaag a 2110921RNAArtificialsiRNA
antisense strandmisc_feature(1)..(1)2'-O-methyl
groupmisc_feature(2)..(2)2'-fluoro
groupmisc_feature(3)..(5)2'-O-methyl group on each
nucleotidemisc_feature(6)..(6)2'-fluoro
groupmisc_feature(7)..(12)2'-O-methyl group on each
nucleotidemisc_feature(13)..(14)2'-fluoro group on each
nucleotidemisc_feature(15)..(15)2'-O-methyl
groupmisc_feature(16)..(16)2'-fluoro
groupmisc_feature(17)..(21)2'-O-methyl group on each nucleotide
109uugccuacgc caacagcacc a 2111019RNAArtificialsiRNA sense
strandmisc_feature(1)..(6)2'-O-methyl group on each
nucleotidemisc_feature(7)..(7)2'-fluoro
groupmisc_feature(8)..(8)2'-O-methyl
groupmisc_feature(9)..(11)2'-fluoro group on each
nucleotidemisc_feature(12)..(19)2'-O-methyl group on each
nucleotide 110gucucuugga uauucucga 1911121RNAArtificialsiRNA
antisense strandmisc_feature(1)..(1)2'-O-methyl
groupmisc_feature(2)..(2)2'-fluoro
groupmisc_feature(3)..(5)2'-O-methyl group on each
nucleotidemisc_feature(6)..(6)2'-fluoro
groupmisc_feature(7)..(13)2'-O-methyl group on each
nucleotidemisc_feature(14)..(14)2'-fluoro
groupmisc_feature(15)..(15)2'-O-methyl
groupmisc_feature(16)..(16)2'-fluoro
groupmisc_feature(17)..(21)2'-O-methyl group on each nucleotide
111ucgagaauau ccaagagaca g 2111219RNAArtificialsiRNA sense
strandmisc_feature(1)..(6)2'-O-methyl group on each
nucleotidemisc_feature(7)..(7)2'-fluoro
groupmisc_feature(8)..(8)2'-O-methyl
groupmisc_feature(9)..(11)2'-fluoro group on each
nucleotidemisc_feature(12)..(19)2'-O-methyl group on each
nucleotide 112cagcuaauuc agaaucauu 1911321RNAArtificialsiRNA
antisense strandmisc_feature(1)..(1)2'-O-methyl
groupmisc_feature(2)..(2)2'-fluoro
groupmisc_feature(3)..(5)2'-O-methyl group on each
nucleotidemisc_feature(6)..(6)2'-fluoro
groupmisc_feature(7)..(13)2'-O-methyl group on each
nucleotidemisc_feature(14)..(14)2'-fluoro
groupmisc_feature(15)..(15)2'-O-methyl
groupmisc_feature(16)..(16)2'-fluoro
groupmisc_feature(17)..(21)2'-O-methyl group on each nucleotide
113aaugauucug aauuagcugu a 2111416DNAArtificialantisense
oligonucleotide 114tcttgcctac gtcata 1611520DNAArtificialantisense
oligonucleotide 115cactcttgcc tacgtcataa
2011620DNAArtificialantisense oligonucleotide 116gcactcttgc
ctacgtcata 2011716DNAArtificialantisense oligonucleotide
117tcttgcctac gccaca 1611816DNAArtificialantisense oligonucleotide
118tcttgcctac gccatc 1611916DNAArtificialantisense oligonucleotide
119tcttgcctac gccaac 1612016DNAArtificialantisense oligonucleotide
120tcttgcctac gtcacc 1612117DNAArtificialantisense oligonucleotide
121ctcttgccta cgtcata 1712218DNAArtificialantisense oligonucleotide
122actcttgcct acgtcata 1812319DNAArtificialantisense
oligonucleotide 123cactcttgcc tacgtcata
1912420DNAArtificialantisense oligonucleotide 124gcactcttgc
ctacgccaca 2012520DNAArtificialantisense oligonucleotide
125gcactcttgc ctacgccatc 2012620DNAArtificialantisense
oligonucleotide 126gcactcttgc ctacgccaac
2012720DNAArtificialantisense oligonucleotide 127gcactcttgc
ctacgtcacc 2012821RNAArtificialsiRNA sense strand 128gagcuugugg
cguaggcaag a 2112921RNAArtificialsiRNA antisense strand
129uugccuacgc cacaagcucc a 2113021RNAArtificialsiRNA sense strand
130gagcugaugg cguaggcaag a 2113121RNAArtificialsiRNA antisense
strand 131uugccuacgc caucagcucc a 2113221RNAArtificialsiRNA sense
strand 132gagcugguga cguaggcaag a 2113321RNAArtificialsiRNA
antisense strand 133uugccuacgu caccagcucc a
2113421RNAArtificialsiRNA sense strand 134aguuggagcu uguggcguag g
2113521RNAArtificialsiRNA antisense strand 135uacgccacaa gcuccaacua
c 2113621RNAArtificialsiRNA sense strand 136aguuggagcu gauggcguag g
2113721RNAArtificialsiRNA antisense strand 137uacgccauca gcuccaacua
c 2113821RNAArtificialsiRNA sense strand 138aguuggagcu ggugacguag g
2113921RNAArtificialsiRNA antisense strand 139uacgucacca gcuccaacua
c 2114021RNAArtificialsiRNA sense strand 140gguaguugga gcuggugacg u
2114121RNAArtificialsiRNA antisense strand 141gucaccagcu ccaacuacca
c 2114221RNAArtificialsiRNA sense strand 142aguuggagcu guuggcguag g
2114321RNAArtificialsiRNA antisense strand 143uacgccaaca gcuccaacua
c 2114421RNAArtificialsiRNA sense strand 144gagcuguugg cguaggcaag a
2114521RNAArtificialsiRNA antisense strand 145uugccuacgc caacagcucc
a 2114621RNAArtificialsiRNA sense strand 146gagcugaugg cguaggcaag a
2114721RNAArtificialsiRNA antisense strand 147uugccuacgc caucagcucc
a 2114821RNAArtificialsiRNA sense strand 148gagcugguga cguaggcaag a
2114921RNAArtificialsiRNA antisense strand 149uugccuacgu caccagcucc
a 2115021RNAArtificialsiRNA sense strand 150aguuggagcu uguggcguag g
2115121RNAArtificialsiRNA antisense strand 151uacgccacaa gcuccaacua
c 2115221RNAArtificialsiRNA sense strand 152aguuggagcu gauggcguag g
2115321RNAArtificialsiRNA antisense strand 153uacgccauca gcuccaacua
c 2115421RNAArtificialsiRNA sense strand 154aguuggagcu ggugacguag g
2115521RNAArtificialsiRNA antisense strand 155uacgucacca gcuccaacua
c 2115621RNAArtificialsiRNA sense strand 156aguuggagcu guuggcguag g
2115721RNAArtificialsiRNA antisense strand 157uacgccaaca gcuccaacua
c 2115821RNAArtificialsiRNA sense strand 158gagcuguugg cguaggcaag a
2115921RNAArtificialsiRNA antisense strand 159uugccuacgc caacagcacc
a 21
* * * * *